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Non-autonomous regulation of bone mass accrual and the role of T-cell protein 
tyrosine phosphatase in the bone regulation of insulin sensitivity 
Tiffany Zee 
 The skeleton is a highly dynamic organ that undergoes constant remodeling to renew 
itself and maintain bone mass.  It is subject to regulation from both hormones produced in 
peripheral tissues and neuronal control by the nervous system.  Recent studies have shown that 
the skeleton is also an endocrine organ, releasing the hormone osteocalcin that increases insulin 
secretion and sensitivity in the pancreas and testosterone production in the Leydig cells of the 
testis.  In my thesis study, I explore both the cell-nonautonomous regulation of osteoblast 
differentiation and the bone regulation of energy metabolism using cell-specific gene 
inactivation in the mouse.  
 Early B-cell factor 1 (Ebf1) is a transcription factor whose inactivation in all cells results 
in high bone mass because of an increase in bone formation.  To test if Ebf1 regulates bone 
formation cell-autonomously, I analyzed Ebf1 pattern of expression and its function in 
osteoblasts.  I show here that in vivo deletion of Ebf1 in osteoblast progenitors does not affect 
osteoblast differentiation or bone formation accrual post-natally, indicating that the phenotype 
described in Ebf1-/- mice is not osteoblast-autonomous. 
 Insulin signaling in osteoblasts contributes to whole body glucose homeostasis in the 
mouse and in humans by increasing the activity of osteocalcin.  The osteoblast insulin signaling 
cascade is negatively regulated by ESP, a tyrosine phosphatase dephosphorylating the insulin 
receptor. Esp is one of many tyrosine phosphatases expressed in osteoblasts, and this observation 
 	  
suggests that other protein tyrosine phosphatases may contribute to the attenuation of insulin 
receptor phosphorylation in this cell type.  In this study, we sought to identify additional PTP(s) 
that like ESP, would function in the osteoblast to regulate insulin signaling and thus affect 
activity of the insulin-sensitizing hormone osteocalcin.  For that purpose, we used as criteria, 
expression in osteoblasts, regulation by isoproterenol, and ability to trap the insulin receptor in a 
substrate-trapping assay.  Here we show that the T-cell protein tyrosine phosphatase (TC-PTP) 
regulates insulin receptor phosphorylation in the osteoblast, thus compromising bone resorption 
and bioactivity of osteocalcin.  Accordingly, osteoblast-specific deletion of TC-PTP (Ptpn2) 
promotes insulin sensitivity in an osteocalcin-dependent manner.  This study increases the 
number of genes involved in the bone regulation of glucose homeostasis. 
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Bone development and physiology 
 A defining feature of higher order organisms is the presence of a bony skeleton.  Totaling 
206 bones, the human skeleton is composed of 80 axial bones and 126 bones appendicular bones.  
The bones are shaped during development, extended during growth, and regenerate continuously 
throughout adulthood.  The skeleton fulfills multiple functions in the body.  First, it provides a 
rigid frame to support the body’s form.  The architecture of the skeleton is such that it provides 
protection to vulnerable soft tissues like the heart and brain, but allows for a wide range of 
movement at the joints, which are formed like a ball-and-socket.  Secondly, the skeleton is a 
store of minerals and growth factors that are confined to the bone extracellular matrix and 
released into circulation upon bone remodeling.  Third, the bone marrow is the site of 
hematopoiesis.  Fourth, it was shown recently that the skeleton is an endocrine organ, releasing 
at least two bone-specific hormones, FGF23 and osteocalcin, that affect other tissues of the body.  
Formed during development, the skeleton undergoes constant postnatal remodeling 
throughout growth and adulthood.  The skeleton is composed predominantly of three kinds of 
cells: the chondrocyte, which form the cartilage; the osteoblast, which are responsible for the 
structure and mineralization of the bone; and the osteoclast, which resorb the matrix for 
remodeling.  Both chondrocytes and osteoblasts are of mesenchymal origin, while the osteoclasts 
differentiate from the hematopoietic lineage. 
 Our understanding of skeletal development and physiology has been greatly improved by 
studies performed in the mouse.  As will be discussed below, many human skeletal genetic 
diseases parallel a corresponding knockout model in the mouse, suggesting that the genetic 
cascades in bone are well conserved between rodents and humans.  
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Development of the skeleton 
The skeleton is formed in the embryo from condensing mesenchyme.  Ossification of the 
mesenchyme occurs through two distinct processes: intramembranous and endochondral 
ossification.  During intramembranous ossification, cells of the mesenchymal condensations 
directly differentiate into osteoblasts, which mature and produce mineralized tissue.  This type of 
ossification forms the bones of the skull, mandibles, and clavicles – bones that are considered 
“flat.” 
In contrast, a process termed endochondral ossification forms “long” bones, such as the 
femur and tibia.  In this 2-step process, condensed mesenchyme first differentiates into 
chondrocytes, which produce a cartilaginous extracellular matrix made up of type II collagen 
fibers, proteoglycans, glycoproteins, and hyluronan, and elastin fibers.  Specification of the 
osteochondroprogenitor requires the transcription factors Runt-related transcription factor 2 
(Runx2) and Sex-determining region Y box 9 (Sox9), both expressed at E10.5.  Sox9, the 
activity of which is partially determined by Sox5 and 6 transcription factors, is the master 
determinant of chondrogenesis (Figure1-1) (Bi et al., 1999; Inada et al., 1999; Kim et al., 1999; 
Lefebvre et al., 2001; Lefebvre et al., 1997).  It is directly responsible for the transcription of the 
proteoglycan gene Aggrecan, and the type II collagen gene Col2α1 (Figure 1-1) (Bell et al., 
1997; Ng et al., 1997). Mutations in the human SOX9 gene lead to camptomelic dysplasia, a kind 
of skeletal dysplasia characterized by bowing of the long bones (Lefebvre et al., 1997). 
The chondrocytes proliferate longitudinally along the bone, secreting extracellular matrix 
and pushing older chondrocytes towards the midsection of long bone.  The older chondrocytes 
undergo hypertrophy and drastically increase their secretion of type X collagen and osteonectin 
into the extracellular matrix (Pacifici et al., 1990).  Chondrocyte maturation is dependent upon 
4 
 
the both the transcription factors runt-related 2 (Runx2) and 3 (Runx3), members of the Runt 
DNA binding domain-containing transcription factor family and are partially redundant in 
chondrocytes (Figure 1-1)	  (Yoshida et al., 2004). 
The second phase of endochondral ossification begins when vessels invade the region of 
hypertrophic chondrocytes.  These chondrocytes then undergo apoptosis and are replaced by 
osteoblasts originating in the bone collar surrounding the cartilage template.  Growth of long 
bones involves the extension of chondrocyte proliferation longitudinally to guide future 
ossification. 
Osteoblasts and the bone extracellular matrix 
The osteoblasts that ossify the bony skeleton are specialized cells that produce an 
extracellular matrix mainly made of type I collagen fibers that become mineralized.  This 
extracellular matrix contains numerous non-collagenous proteins.  Mineralization of the bone 
extracellular matrix involves deposition of Ca5(PO4)3(OH) hydroxyapatite within the fibrous 
scaffold.  Mineralization gives bones their characteristic rigidity and resilience to compressive 
force.   
Transcriptional regulation of osteoblast differentiation  
Runx2, responsible for terminal differentiation of chondrocytes, is also expressed in 
osteoblasts where it is the master transcriptional regulator of osteoblast specification and 
differentiation.  Its Runt DNA-binding domain is a clamp-like structure that encircles the DNA 
for a stable protein-DNA interaction.  The Runt family of transcription factors also contains a 
conserved C-terminal proline-serine-theronine-rich (PST) domain and a nuclear localization 
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signal.  However, Runx2 is unique from Runx1 and 3 in that it has three activation domains that 
control its transcription activation and prevent interaction with the Runx transcriptional partner 
Cbfβ (Thirunavukkarasu et al., 1998).  
Runx2 expression is initiated in the sites of skeletal condensation at E10.5 and increases 
steadily in the sites of ossification until birth (Ducy et al., 1997).  Post-natally, Runx2 expression 
becomes restricted to cells of the osteoblast lineage, where it promotes bone formation by 
differentiated osteoblasts (Ducy et al., 1999).  Mice lacking Runx2 die at birth from severe 
skeletal dysplasia, lacking any ossification (Otto et al., 1997).  In humans, missense mutations in 
Runx2 are associated with cleidocranial dysplasia, a disorder characterized by collarbone and 
cranium deformities and short stature from underdeveloped bones and joints (Mundlos et al., 
1997) (Lee et al., 1997). 
As the master transcriptional regulator of osteoblastogenesis, Runx2 is regulated at 
several levels (Fig. 1-1).  At the level of expression, Runx2 is positively regulated by muscle 
segment homeobox homolog 2 (Msx2) at the sites of endochondral ossification, and bagpipe 
homeobox gene (Bapx1) in the axial skeleton.  Both Msx2-/- and Bapx1-/- mutant mice display 
deficiencies in ossification due to decreased expression of Runx2 in the osteoblasts (Satokata et 
al., 2000; Tribioli and Lufkin, 1999).  Humans with loss-of-function mutations MSX2 develop 
enlarged parietal foramina (PFM), characterized by openings in the skull, while gain-of-function 
MSX2 mutations result in Boston-type craniosynostosis, a disease marked by premature 
ossification and high bone density of craniofacial elements (Karsenty, 2008; Satokata et al., 
2000; Wilkie et al., 2000).  In contrast, Homeobox A2 (Hoxa2) negatively regulates Runx2 
expression, and Hoxa2-/- mice display ectopic bone formation in the second branchial arch as a 
result of increased Runx2 expression (Kanzler et al., 1998).   
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The DNA binding domain of Runx2 is also a site of post-translational regulation.  
Though Runx2 is expressed at E10.5, ossification is undetectable until E14.5.  Twist-1 is a basic 
helix-loop-helix (bHLH) transcription factor containing a Twist box, an interaction domain.  The 
Twist box interacts transiently with the Runx2 runt domain to attenuate its activity from the 
E10.5 to E14.5 window and thus inhibit osteoblast differentiation.  At E14.5, Twist-1 expression 
considerably decreases, permitting Runx2-dependent ossification to start (Bialek et al., 2004).  
Accordingly, in humans, a lack of Twist-1 results in premature ossification, and mutations within 
TWIST-1 are a major cause of craniosynostosis (el Ghouzzi et al., 1997).  Stat1 (signal transducer 
and activator of transcription 1) binds to the Runx2 runt-domain, where it inhibits Runx2 nuclear 
translocation.  Due to increased Runx2 transcriptional activity, Stat1-/- mice develop high bone 
mass (Kim et al., 2003a).  A zinc-finger adaptor protein, Schnurri-3, regulates Runx2 
degradation by recruiting E3 ubiquitin ligase WWP1 to Runx2 (Jones et al., 2006). 
In contrast, Satb2 (Special AT-rich sequence-binding protein 2), a nuclear matrix protein, 
promotes Runx2 activity in two ways:  it interacts directly with Runx2 to enhance its DNA 
binding and transactivation ability, and secondly, represses expression of the Runx2-inhibitor 
Hoxa2.  Humans with a deficiency in SATB2 thus develop abnormal craniofacial patterning 
(Dobreva et al., 2006). 
Downstream of Runx2 is Osterix, a zinc-finger containing transcription factor specific to 
osteoblasts and chondrocytes that is necessary for further osteoblast differentiation and mineral 
deposition (Nakashima et al., 2002).  Like Runx2, it is required both during development and 
post-natal growth for new bone formation during growth and remodeling (Zhou et al., 2010).  
Osterix activity is, in part, determined by its interaction with the transcription factors, nuclear 
factor of activated T-cells NFATc1 and c2 (Koga et al., 2005).   
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Terminal osteoblast differentiation, defined by the ability of the osteoblast to mineralize 
the extracellular matrix, is dependent upon ATF4 (activating transcription factor 4), a member of 
the family of the ATF-CREB bZIP family of transcription factors that contains a basic leucine-
zipper.  ATF4 stimulates the synthesis of type I collagen by promoting amino acid import into 
the osteoblasts (Harding et al., 2003).  In addition, ATF4 regulates Rankl expression to control 
osteoclast differentiation, and thus bone resorption, as discussed in a subsequent section 
(Elefteriou et al., 2006). 
 Molecular regulation of ATF4 activity occurs at the post-translational level.  The leucine 
zipper domain of ATF4 is subject to phosphorylation.  RSK2, a growth factor-related kinase, 
phosphorylates ATF4 to promote its transcriptional activity.  Loss-of-function mutations in RSK2 
result in Coffin-Lowry syndrome, a multi-system disorder that also affects bone growth. 
Individuals with Coffin-Lowry, in addition to developmental delays and cardiac abnormalities, 
have brittle bones and short stature as a result of decreased ATF4 activity (Yang et al., 2004).  
ATF4 activity, like that of Runx2, is also enhanced by the binding of Satb2 (Dobreva et al., 
2006).  In contrast, Nf1 (Neurofibromatosis 1), a Ras-GTPase activating protein, is a negative 
regulator of Atf4 activity.  It is an inhibitor of Ras/MAPK/Rsk2 signaling, of which ATF4 is 
downstream. Deletion of Nf1 specifically in osteoblasts results in increased collagen synthesis 
(Elefteriou et al., 2006).   
Ebf1 and its regulation of bone mass accrual 
An interesting candidate for and additional level of regulation of osteoblast 
differentiation is the transcription factor Early B-cell factor 1 (Ebf1).  Ebf1 belongs to the 
Ebf/COE family of transcription factors.  Members of this family share a highly conserved 
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DNA-binding domain, a transcription factor immunoglobulin (TIG/IPT) domain, and an atypical 
Helix-Loop-Helix (HLH) motif.   The DNA binding domain contains an unusual zinc-finger like 
motif, designated the “zinc-knuckle,” that is essential for its transcriptional activity (Figure 1-2).  
Ebf1 binds to DNA as a symmetric dimer in a stable configuration that maximizes protein-DNA 
contact at 3000Å2.  The observation that Ebf1 has one of the largest known protein-DNA 
interfaces led to the hypothesis that Ebf1 may be a “pioneer” transcription factor that acts early 
in cell specification to stabilize chromatin accessibility for downstream factors (Hagman et al., 
1995; Treiber et al., 2010a). 
There are four Ebf paralogs in vertebrates (Ebf2, 3, and 4).  Ebf1, working in concert with 
E2A and Pax5, is a principle determinant of B-cell fate specification and commitment and 
expressed in all stages of B cell differentiation.  Common lymphoid progenitors lacking Ebf1 
disproportionately differentiate into myeloid and T cell lineages at the expense of mature B cells.  
Specifically, Ebf1-/- cells arrest at the pre-pro-B stage (Lin and Grosschedl, 1995; Treiber et al., 
2010b). By comparison Pax5-/- (Paired box 5), the major transcriptional guardian of B cell 
identity, arrest at the pro-B stage (Urbanek et al., 1994) (Nutt et al., 1997) (Cobaleda et al., 
2007).  Overexpression of Ebf1 promotes B cell development at the expense of these lineages.  
Ebf1 acts to regulate expression of its target genes involved in pre-B cell receptor and Akt 
signaling, cell adhesion, and migration.  Ebf1 activated targets are H3K4 methylated or H3 
acetylated, while its repressed targets demonstrate loss of activating chromatin marks and a gain 
of H3K27 trimethylation (Treiber et al., 2010b). 
 Runx1 has recently been identified as an important transcription factor regulating Ebf1 
expression and activity.  Runx1 and Ebf1 regulate early B cell lineage specification genes and Ig 
gene rearrangement synergistically (Lukin et al., 2010).  The activity of Ebf1 is in part 
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determined by Runx1, which binds to the Ebf1 promoter region to drive its expression (Seo et al., 
2012). 
 Ebf1 shares approximately 90% identity with its paralogues Ebf2 and 3.  All three 
members are expressed in the olfactory epithelium, spinal cord and hindbrain regions.  Ebf1-/- 
mice have normal olfactory neurons, and it is believed that its redundancy with Ebf2 and 3 may 
account for the lack of an olfactory neuron phenotype in Ebf1-/- mice (Wang et al., 1997).  In 
addition to its expression in olfactory sensory neurons, Ebf1 is present in the embryonic striatum 
where no other Ebf gene is expressed.  It is important for mantle cell differentiation and 
migration in neuroepithelial progenitors (Garel et al., 1999), as well as striatonigral medium 
spiny neurons in the striatum (Lobo et al., 2008). 
 More importantly for our purposes, previous studies have implicated additional function 
for Ebf1in the mesenchymal lineage, specifically in adipocytes and osteoblasts.  It is important to 
stress however, that the Ebf1 putative role in adipogenesis has been studied exclusively in cell 
culture through the use of the cell line 3T3L1 (Akerblad et al., 2002; Jimenez et al., 2007).  
These cells normally adopt a fibroblast-like morphology, but under certain cell culture 
conditions, 3T3L1 cells express peroxisome proliferator-activated receptor γ2, the master 
transcriptional regulator of adipogenesis.  Continued “differentiation” of these cells results in the 
production of trigylcerides and lipid droplets.  The conditions that promote 3T3L1 adipocyte-like 
differentiation include growth in medium containing either a PPARγ agonist (for example, 
Rosiglitazone), or a cocktail of pro-adipogenic agents: dexamethasone (a steroid), insulin, and 
IBMX (an immunosuppressant that raises cAMP levels) termed DMI (Green and Kehinde, 1975; 
Gregoire et al., 1998). 
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Jimenez et al. demonstrated that DMI differentiation induces an increase in the 
expression of Ebf1 and Ebf2 prior to the induction of PPARγ2 and CCAAT/enhancer-binding 
protein alpha (C/EBPα), a bZIP transcription factor part of a feed-forward loop that increases 
PPARγ2 activity and promotes adipocyte-specific gene expression (Jimenez et al., 2007).  3T3L1 
cells lacking Ebf1 have impaired adipogenesis in DMI medium, while Ebf1 overexpression 
increases the formation of lipid droplets (Akerblad et al., 2002).  These observations led to the 
hypothesis that Ebf1 may be a pre-PPARγ2 transcriptional determinant of adipogenesis.  
Ebf1-/- mice are dwarfed and demonstrate increased bone mass and diminished 
subcutaneous and abdominal white adipose depots.  The observations from cell culture 
experiments together with the lack of white fat depots in Ebf1-/- mice suggest that Ebf1 promotes 
adipogenesis. Since both adipocytes and osteoblasts are derived from mesenchymal cells, it has 
been hypothesized that Ebf1 could be an early mesenchymal transcriptional determinant of the 
adipocyte versus osteoblast cell fate decision (Fretz et al., 2010; Hesslein et al., 2009). 
The metabolic profile of Ebf1-/- mice is expectedly altered.  Previous analysis shows that 
these mice are chronically hypoglycemic with increased insulin sensitivity.  They display 
increased energy expenditure and food intake, despite a slightly cachectic appearance.  Due to 
increased bone mass and decreased adipose, serum osteocalcin and leptin levels are increased 
and decreased, respectively, in these mice.  Interestingly, Ebf1-/- mice display an increase in 





Antagonistic to the bone-building properties of osteoblasts, osteoclasts resorb the organic 
and inorganic components from the bone matrix.  The balance between the two opposing forces 
is integral to the constant process of bone regeneration, termed remodeling.  A defect in 
resorption results in osteopetrosis, a condition characterized by hardening of the bone due to the 
imbalance toward bone formation.  This condition also disrupts the brittleness of mineralized 
bone trabeculae, affecting hematopoiesis due to constriction of the bone marrow.  In contrast, an 
increase in osteoclast function results in the condition osteoporosis.  This disease, common 
especially in post-menopausal women, is marked by decreased bone mass and an increased risk 
of fractures.   
Osteoclast structure and function 
The osteoclast is a large, multinucleated cell formed from the fusion of 15-20 
differentiated macrophages (Figure 1-3) (Boyle et al., 2003; Walker, 1975). To resorb the 
mineralized bone matrix, the osteoclast attaches its ends to the bone matrix using specialized 
attachment molecular and focal adhesions to form the sealing zone.  Lysosomal vesicles are then 
exocytosed towards the bone surface, forming a cavity between the osteoclast and bone surface. 
The plasma membrane that forms the transportation border folds upon itself to facilitate the high 
rate of exocytosis, adopting a “ruffled” appearance.  The process of establishing an osteoclast 
resorption lacuna requires polarization of the osteoclast, and the cytoskeleton accommodates 
these changes by reorganizing its cytoskeleton. C-src, a tyrosine kinase, is important for the 
phosphorylation and reorganization of integrins (such as αvβ3) and focal adhesions. A lack of c-
src results in severe osteoclast dysfunction and osteopetrosis (Soriano et al., 1991) 
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The first step of bone resorption is dissolution of the inorganic matrix, achieved by 
acidification of the resorptive lacunae (Baron et al., 1985).  Protons are generated by carbonic 
anhydrase II (CAII) and then transported to the lacunae by Tcirg1, a vacuolar proton ATPase 
expressed on the ruffled membrane (Blair et al., 1989; Kenny, 1985; Raisz et al., 1988).  The 
acid microenvironment created by osteoclasts dissolves hydroxyapatite, releasing calcium and 
phosphate ions into the lacunae.  These ions are absorbed by the osteoclast via endocytosis and 
transported across the cell and then released into the blood.  Mutations in the human TCIRG1 
gene account for approximately half of human malignant infantile osteopetrosis cases (Frattini et 
al., 2000; Susani et al., 2004)  
Maintenance of electroneutrality in the lacunae and osteoclast is also important for 
resorption.  Chloride channel 7 (CLCN-7), localized to the ruffled membrane, transports chloride 
anions to the lacunae to balance the influx of protons into the lacunae.  This protein is 
responsible for bringing the microenvironment pH to ~4.5 (Schlesinger et al., 1997).  Mutations 
in CLCN-7 disrupt the acidification of the lacunae, and result in osteopetrosis by definition 
(Kornak et al., 2001). A chloride/bicarbonate exchanger, localized on the membrane facing the 
extracellular fluid, corrects the osteoclast’s internal proton efflux (Teti et al., 1989). 
This process of bone resorption exposes the organic matrix, largely composed of type I 
collagen.  Cathepsin K (Ctsk) is a collagenolytic protease that is released into the resorption 
lacunae to degrade the demineralized collagen matrix.  It is processed in the Golgi and 
transported to the ruffled membrane, where it is secreted into the lacunae through exocytosis.  A 
lysosomal protease, Ctsk is active in the acid pH of the lacunae, where it completes the 
resorption process by catabolizing the exposed collagen matrix (Bossard et al., 1996; Yamaza et 
al., 1998).  Mice lacking the Ctsk gene possess fully differentiated osteoclasts, but develop 
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osteopetrosis due to the inability of the osteoclast to remove demineralized bone (Saftig et al., 
1998).  Pycnodysostosis, an autosomal recessive form of osteopetrosis characterized by short 
stature, craniofacial abnormalities, and defective bone resorption, is caused by a mutation in 
CTSK (Gelb et al., 1996). 
Mechanisms regulating osteoclast differentiation 
Osteoclasts are of hematopoietic monocyte/macrophage lineage, formed in the bone 
marrow by the fusion of differentiated macrophages.  A combination of transcription factors and 
extracellular signals are necessary for monocytes to fuse and differentiate into multinucleated, 
resorptive osteoclasts (Figure 1-4).   
Transcriptional Control of Osteoclast differentiation 
Unsurprisingly, the transcription factors necessary for monocyte differentiation are also 
essential for early osteoclastogenesis. PU.1, a transcription factor specific to hematopoietic cells, 
is the earliest known transcription factor known for early macrophage determination. Lack of a 
functional PU.1 gene, characterized by an absence of macrophages and osteoclasts, is lethal 
(Tondravi et al., 1997). 
Downstream of PU.1 are the microphythalmia-associated family of transcription factors 
(MITF), which include TFE3, TFEB, TFEC, and MITF (Weilbaecher et al., 2001).  These helix-
loop-helix transcription factors help to specify the differentiated macrophage/osteoclast 
precursor, and in later stages, interact with PU.1 to increase expression of osteoclast genes like 
Ctsk and Trap (Tartrate-resistant acid phosphatase), a histological marker of mature osteoclast 
function (Luchin et al., 2001). 
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The AP-1 transcription complex, which is downstream of JNK MAPK signaling, includes 
c-Fos, c-Jun, and JunB, and Fra/Fosl1.  c-Fos itself is necessary for expression of the AP-1 
transcriptional component Fra1/Fosl1.   Though it is still unclear what are the targets of the AP-
1 complex, it is known that its activity is required for osteoclastogenesis.  Mice lacking genes 
involved in the AP-1 complex (Fos-/- and Fosl1-/-) develop a sufficient number of macrophages, 
but lack mature osteoclasts (Wagner and Matsuo, 2003) (Matsuo et al., 2000) (Teitelbaum and 
Ross, 2003) 
After osteoclast cell fate commitment, the osteoclast precursors fuse to form a 
multinucleated cell.  The master regulator of osteoclast cell fusion and maturation is the nuclear 
factor of activated T-cells c1 (NFATc1). It is downstream of NF-κB signaling, and cooperates 
with c-Fos synergistically on the promoter of many functional resorptive genes, such as TRAP, 
CAII, and Ctsk (Takayanagi et al., 2002).  Deletion of Nfatc1 in the mouse results in a form of 
osteopetrosis lacking mature osteoclasts (Aliprantis et al., 2008). 
Paracrine factors affecting osteoclastogenesis 
Differentiation, proliferation, and survival of the osteoclast precursors are dependent on 
the paracrine factor M-CSF (macrophage colony-stimulating factor).  M-CSF is secreted from 
nearby osteoblasts and binds to its receptor on immature macrophages, promoting MITF activity 
in a MAPK-dependent manner (Weilbaecher et al., 2001).  In addition, M-CSF stimulates the 
ERK1/2 and PI3K/Akt signaling cascades to promote survival and proliferation of the immature 
macrophages (Gingery et al., 2003). Lack of M-CSF (op/op) in the mouse results in osteoclast 
deficient osteopetrosis (Kodama et al., 1991). 
A second paracrine factor and critical determinant of osteoclast maturation is receptor 
activator of nuclear factor kappa B ligand (RANKL) signaling.  RANKL, a member of the tumor 
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necrosis factor family, is expressed on the surface osteoblasts/stromal cells where it binds to the 
receptor RANK on neighboring osteoclast precursors (Lacey et al., 1998; Yasuda et al., 1998b). 
RANK activation recruits TNF receptor associated factor 6 (TRAF6), an adaptor protein that, in 
cooperation with c-Src, activates Akt/PI3K signaling pathway to initiate cellular reorganization 
of integrins.  In addition, RANKL-recruited TRAF6 initiates the NF-κB pathway and all three 
MAPK pathways to promote the activity of osteoclast differentiation transcription factors (Bai et 
al., 2008; Lamothe et al., 2007). 
The RANKL/RANKL/OPG system 
RANKL is the most powerful activator of osteoclastogenesis.  It was first discovered as a 
factor that was both necessary and sufficient for the ex vivo differentiation of bone marrow-
derived osteoclast precursor cells into mature osteoblasts. (Lacey et al., 1998; Udagawa et al., 
1990).  Accordingly, mutations in the RANKL gene result in osteopetrosis in both mouse and 
humans (Kong et al., 1999; Sobacchi et al., 2007). 
Though osteoblasts are a major source of RANKL for the activation of osteoclast 
maturation, they are also a negative regulator of osteoclast differentiation.  Osteoprotegrin (OPG) 
is a decoy receptor belonging to the TNF receptor family that is secreted by osteoblasts/stromal 
cells.  By mimicking RANK receptor structure, OPG competitively hinders RANKL binding to 
its receptor on osteoclast precursors (Figure 1-5) (Simonet et al., 1997; Takahashi et al., 1988; 
Takai et al., 1998; Yasuda et al., 1998a). A shift in the equilibrium between osteoblast RANKL 
and OPG expression, the ratio of which is often used as an index for osteoclastogenesis, can thus 
affect osteoclast differentiation and resorptive activity.  One such example is parathyroid 
hormone (PTH), which enhances bone resorption.  PTH binds to its receptor on the osteoblast 
where it simultaneously increases the expression of RANKL while inhibiting that of OPG (Huang 
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et al., 2004).  In contrast, estrogens have been shown to enhance OPG expression in osteoblasts, 
an observation suggestive of its role in the attenuation of bone resorption (Hofbauer et al., 1999). 
An osteoblast transcriptional determinant of Rankl expression is ATF4.  ATF4-activated 
Rankl expression is promoted specifically by Protein kinase A (PKA) signaling in the osteoblast.  
The osteoporotic phenotype observed in Neurofibromatosis type I (and phenocopied by Nf1osb-/-  
mice) is accounted for by the increase in PKA signaling and increased Atf4-activated Rankl 
expression (Elefteriou et al., 2006). 
Bone is an endocrine organ 
A major advance in skeletal biology and in endocrinology has been the recent realization 
that the skeleton is an endocrine organ.  One example of these is FGF23, which is released into 
circulation from osteoblasts and part of a feedback loop regulating phosphate homeostasis 
(Kawata et al., 2007; White et al., 2000).  The other hormone is osteocalcin, a small protein 
secreted specifically by the osteoblasts and stored in the bone matrix.  Upon bone resorption, 
osteocalcin is decarboxylated, i.e. activated, in the resorptive lacunae and released into the 
circulation where it promotes insulin secretion, insulin sensitivity, energy expenditure, and 
testosterone production (Ferron et al., 2010a; Lee et al., 2007; Oury et al., 2011). 
FGF23 
 The cell’s need for phosphate is extensive.  Phosphate is required for DNA and RNA, 
energy metabolism, as a second messenger in signal transduction, and for the modification of 
proteins and lipids.  It is also needed for bone mineralization, and therefore not surprising that 
the majority of the body’s phosphate is stored in the mineralized bone extracellular matrix and 
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released by bone resorption as necessary.  A lack of phosphate in the body leads to the softening 
of bones and increase risk for fractures that defines rickets in children, or osteomalacia in adults 
(Jonsson et al., 2003; Kawata et al., 2007; Yamazaki et al., 2002).   
FGF23 is a hormone that normalizes phosphate levels in the body.  Increased amounts of 
phosphate levels in the serum are detected by the osteoblast and osteocytes, stimulating the 
production of FGF23, which is then secreted into circulation.  FGF23 binds to a FGF1 
receptor/Klotho complex in the kidney where it inhibits expression of the tubular renal phosphate 
transporters, NPT2a and NPT2c, in the kidney (Gattineni et al., 2009; Urakawa et al., 2006).  As 
a consequence of FGF23 action in kidney, phosphate reabsorption in the proximal tubule is 
decreased while urinary phosphate excretion is increased.     
Hypophosphatemic rickets/osteomalacia is characterized by a mutation that leads to the 
overproduction or increased stability of FGF23.  In autosomal dominant rickets, a mutation in the 
Fgf23 gene protects the protein from posttranslational cleavage (White et al., 2001) (Shimada, 
Endocrinology 2002).  X-linked hypophosphatemia (XLH) is caused by mutations in the 
protease PHEX that also prevents FGF23 cleavage(Campos et al., 2003).  The last example of 
FGF23-dependent osteomalacia is tumor-induced osteomalacia, where FGF23 is overproduced 
as a consequence of osteocarcinoma (Shimada et al., 2001). 
Osteocalcin 
 Osteocalcin, or Bone-GLA protein, is a 5.8 kDa protein specifically secreted into 
circulation by osteoblasts and used for decades as a biochemical marker of bone formation.  
Recent studies from our lab have shown that osteocalcin is in fact a hormone that, once 
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decarboxylated, stimulates insulin production, insulin sensitivity, energy expenditure, and 
testosterone production(Lee et al., 2007; Oury et al., 2011).   
 Osteocalcin is produced in the osteoblast where it undergoes posttranslational processing.   
In the endoplasmic reticulum, vitamin-K dependent protein carboxylase (VKD) modifies the 
three glutamic acid residues of osteocalcin into γ-carboxyglutamic acid (Gla) residues, a process 
requiring both vitamin K and carbon dioxide (Hauschka et al., 1989a; Lian and Friedman, 1978).  
Carboxylated osteocalcin is then secreted into the bone matrix, where it has a high affinity for 
hydroxyapatite (Hauschka et al., 1989a) 
Through the resorptive activity of osteoclasts, osteocalcin is released into circulation.  As 
it passes through the acidic environment of the resorption lacunae, the post-translational 
carboxylation of osteocalcin is partially reversed. The undercarboxylated form of osteocalcin, 
where Glu residue 13 is uncarboxylated, is an active circulating hormone (Ferron et al., 2010a). 
Osteocalcin promotes insulin secretion and sensitivity 
Circulating, GLU13-undercarboxylated osteocalcin increases insulin secretion in the β-
islet cells of the pancreas in two ways: by increasing β-islet cells proliferation, and by 
stimulating insulin production in the β-islet cells.  Coculture experiments demonstrate that 
pancreatic islets increase their expression of the Insulin genes and of the proliferation genes 
CyclinD1 and CyclinD2 in the presence of primary osteoblasts, an effect that is dependent upon 
Osteocalcin expression (Lee et al., 2007).  
In vivo, mice lacking osteocalcin (Ocn-/-) display hyperglycemia and hypoinsulinemia.  
The pancreases of these mice have decreased β-islet size and number, insulin content, and 
proliferation.  As a result, mice lacking osteocalcin are glucose intolerant and resistant to glucose 
stimulated insulin secretion (Lee et al., 2007). 
19 
 
 In various human studies, total and undercarboxylated osteocalcin levels have been 
correlated with lower glucose and increased insulin levels, suggesting that the role of osteocalcin 
in the regulation of glucose homeostasis is conserved in humans (Im et al., 2008)	  (Kindblom et 
al., 2009)	  (Fernandez-Real et al., 2009)	  (Winhofer et al., 2010)	  (Hwang et al., 2009)	  (Shea et al., 
2009).  In addition, osteopetrotic patients display a decrease in undercarboxylated osteocalcin 
levels accompanied by an increase in insulin levels, suggesting that the osteocalcin activation 
process is also conserved (Ferron et al., 2010a). 
Osteocalcin promotes testosterone production and male fertility 
 In addition to its role in promoting glucose homeostasis, osteocalcin stimulates 
testosterone production in Leydig cells of the testes.  In mice lacking Osteocalcin, testis size was 
significantly lower with a corresponding decrease in testosterone production in the blood.  
Osteocalcin, released by the bone, binds to its receptor Gprc6a on the surface of Leydig cells.  
Upon binding of osteocalcin to Gprc6a, CREB is phosphorylated by PKA, and it then activates 
multiple genes that are involved in the synthesis of testosterone – StAR, Cyp11, Cyp17, and 3β-
HSD. Increased testosterone production in these mice directly resulted in increased sperm 
production	  (Oury et al., 2011).   
 One human association study performed in Japanese male diabetic patients demonstrated 
that increased undercarboxylated osteocalcin levels were correlated with free testosterone in the 
serum	  (Kanazawa et al., 2012).  In addition, osteocalcin was correlated with increased 
testosterone levels during post-pubertal male growth (Kirmani et al., 2011). 
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Insulin promotes osteocalcin activation  
Upon the discovery that osteocalcin stimulates insulin production, it became a question 
whether insulin would, in turn, reciprocate regulation upon osteocalcin activity in a feed-forward 
or feed-back mechanism (Karsenty and Oury, 2012).  
Insulin signaling 
The functional insulin receptor (InsR) is a transmembrane tyrosine kinase receptor (RTK) 
homodimer formed by α and β subunits connected by a disulfide bond.    The β subunit spans the 
cell membrane and contains the tyrosine kinase on it cytosolic face, while the external α subunit 
is exposed to the cell surface where it physically binds to its ligand insulin.  Once insulin binds 
to its receptor, InsR becomes phosphorylated, and then autophosphorylated on three tyrosine 
residues.  This results in a structural reconfiguration and internalization of the receptor into a 
vesicle that enables recruitment of specific downstream effectors and subsequent phosphate 
transfer	  (Schlessinger, 2000).    
There are many intracellular substrates of the insulin receptor, including the insulin-
receptor substrates (IRSs), Src-homology-2-containing proteins (SHC), Cas-Br-M ectropic 
retroviral transforming sequence homologe (Cbl), Grb2-associated binder-1 (Gab-1) and STAT 
proteins (Figure 1-6).  They become tyrosine phosphorylated upon binding to the insulin 
receptor, and thus become a “docking site” for downstream adaptor proteins.  (Taniguchi et al., 
2006). 
Two main signaling cascades, the PI3K/AKT/PKB (PKB) and RAS-mitogen-activated 
protein kinase pathway (MAPK) pathways, are involved in insulin signaling.  These pathways 
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contain many components, some of which cooperate and converge to promote glucose uptake 
from the cell and thus affect cell growth, proliferation, and differentiation 
Activated by phosphorylated IRS-1, Phosphatidylinositol 3-kinase (PI3K) catalyzes the 
formation of the lipid second messenger PIP3 from PIP2 and ATP.  This leads to recruitment of 
several PIP3-dependent serine/threonine kinases (PDK) and AKT/PKB to the plasma membrane, 
where PDKs activates AKT/PKB.   AKT/PKB targets: glycogen synthase kinase (GSK) to 
decrease glycogen synthesis; AKT substrate (AS160) to increase glucose transporter localization 
to the plasma membrane; mTOR to affect protein synthesis; and importantly, phosphorylates the 
Forkhead box protein O1 (FOXO1) transcription factor.   The posttranslational modification of 
FOXO1 prevents it from entering the nucleus, and allows the expression of gluconeogenic and 
lipogenic enzymes. 
Insulin signaling in the osteoblast 
Deletion of the insulin receptor in osteoblasts (InsRosb-/-) results in increased adiposity, 
glucose intolerance, and insulin resistance in mice on a normal chow diet.  This is in contrast to 
the deletion of the insulin receptor in skeletal muscle and white adipose tissue – mice do not 
display either phenotype unless they are challenged by a high fat diet, suggesting that bone is a 
significant contributor to whole body glucose homeostasis.  This occurs because insulin 
signaling in osteoblasts promotes osteocalcin activation.  Insulin signaling in the osteoblast 
affects the osteoblast production of osteocalcin in two ways: by promoting bone resorption and 
stimulating osteoblast development (Ferron et al., 2010a; Fulzele et al., 2010).   
Opg expression is decreased upon the activation of the insulin receptor.  The insulin 
signaling effectors Akt and FOXO1 in other cell types are also effectors in the osteoblast.  
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Phosphorylation of Akt, and subsequently FOXO1, results in the inhibition of Opg expression 
and increase in osteoclast function.  The resorption lacunae that is necessary for osteocalcin 
release and activation is thus formed (Figure 1-7).  Deletion of FOXO1 specifically in 
osteoblasts results in a gain of osteocalcin bioactivity, thus affecting whole-body glucose 
homeostasis (Ferron et al., 2010a).  
As it does in other insulin-responsive cells, the insulin receptor affects osteoblast 
proliferation, survival, and differentiation.  By increasing Twist-1 inhibition of Runx2, a direct 
transcriptional regulator of Osteocalcin, insulin increases osteoblast proliferation and the 
production of osteocalcin, at the total and undercarboxylated level.  Mice lacking InsR 
specifically in the osteoblasts display decreased osteoblast and bone formation rate, and as a 
result have decreased serum osteocalcin levels (Fulzele et al., 2010).  FOXO1 may also be a 
mediator of the insulin control of osteocalcin production, as it is a major transcriptional regulator 
of osteoblast proliferation and acts in concert with ATF4 in the nucleus to control amino acid 
import and collagen synthesis (Rached et al., 2010b). 
Regulation of insulin signaling by protein tyrosine phosphatases 
 Insulin resistance is a condition where cells fail to respond adequately to insulin and thus 
do not efficiently uptake glucose, amino acids, and/or lipids, resulting in their accumulation in 
the blood.  If the pancreas is unable to produce enough insulin to clear the accrued glucose and 
free fatty acids, this condition develops into type 2 diabetes. Thus, it became particularly 
important to identify factors that attenuate the insulin signal.   Protein tyrosine phosphatases 
(PTPs) are a family of enzymes that remove phosphate groups from phosphorylated tyrosine 
residues.  They have since been identified as essential regulators of both insulin receptor and 
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insulin receptor substrate phosphorylation, the first “node” of insulin action (Taniguchi et al., 
2006). 
Protein tyrosine phosphatase catalytic mechanism 
Protein-tyrosine phosphatases (PTPs) are defined by a conserved signature motif 
[I/V]HCXXGXXR[S/T], termed the “WPD loop,” containing an essential cysteine in the 
catalytic site, the thiolate ion of which acts as a nucleophile to dephosphorylate its substrate 
(Tonks, FEBS Letters 2003). Catalysis begins first from nucleophilic attack by the thiolate ion 
upon the substrate phosphate group, thus binding the PTP to its substrate (Figure 1-8).  This 
results in an 8-12 Å conformational change where the aspartic acid residue is brought close to the 
phosphoryl-cysteine intermediate.  The aspartic acid residue then protonates the substrate 
tyrosyl-leaving group, thus releasing the substrate.  In the second step, the deprotonated aspartic 
acid residue acts as a base to hydrolyze the phosphoryl-cysteine intermediate and release the 
phosphate group.  This last step regenerates PTP activity (Figure 1-7) (Tonks, 2003). 
Ligand-induced receptor tyrosine kinase (RTK) phosphorylation may be dependent upon 
the inactivation of PTPs.  The observation that PTP inhibitors increase RTK autophosphorylation 
suggests that functional RTK dimers exist in the absence of ligand binding and that PTP activity 
prevents RTK phosphorylation (Schlessinger, 2000).  One proposed model suggests that ligand-
RTK binding induces activation of an NADPH oxidase, resulting in the generation of reactive 
oxygen species (ROS). The presence of ROS reversibly oxidizes the vulnerable thiolate ion of 
the PTP catalytic cysteine, converting it to sulfenic acid and then sulfenyl amide, preventing 
substrate interaction.  By inactivating the PTP, RTK phosphorylation is permitted.  PTP activity 
is restored upon exposure of the sulfenyl amide ion to glutathione or thioredoxin in the 
24 
 
intracellular fluid, ready to bind dephosphorylate its next substrate (Figure 1-9)	  (Meng et al., 
2000; Meng et al., 2002; Salmeen et al., 2003; Tonks, 2005; van Montfort et al., 2003) 
There are three classes of PTPs: classical, which dephosphorylate tyrosine resides; dual 
specificity, which dephosphorylate both serines/threonine and tyrosine residues; and 
pseudophosphatases, which lack a functional catalytic site but can affect RTK signaling in 
alternate ways.  The classical PTPs are further divided into subgroups: receptor and non-
receptor, or cytoplasmic, PTPs. Twelve of the receptor PTPs contain a second pseudo-
phosphatase domain (D2) that has been shown to be inactive but necessary for the specificity and 
stability of the protein (Tonks, 2005).  However, in the case of PTPRA, the D2 domain displays 
low residual activity	  (Krueger et al., 1990).  
Dual-specificity PTPs are structurally similar to classical PTPs, but their active site 
accommodates phosphorylated serine and threonine residues.  Preferential phosphorylation of the 
serine/threonine instead of the tyrosine residue, or vice versa, has been demonstrated for some of 
phosphatases in this class (Poon and Hunter, 1995; Schumacher et al., 2002).   
Pseudophosphatases are those whose phosphatase domains are catalytically inactive.  
Originally believed to be nonfunctional remnants of evolution, deletions of particular 
pseudophosphatases have been shown to have disease-related consequences (Azzedine et al., 
2003).  Furthermore, these proteins maintain their ability to interact with other PTPs in a 
dominant-negative manner (Kim et al., 2003b; Tonks, 2005).  
PTP substrate-trapping mutants 
A useful biochemical tool in investigating the targets of PTPs is the use of substrate-
trapping mutants.  PTPs can be mutated into two types of substrate-trapping mutants, C/S and 
D/A.  C/S mutants alter the catalytic cysteine to a serine, thereby forming a stable PTP–Ser–
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PO3–S complex.  This substrate mutant permits binding (similar Km) but blocks catalysis 
(decreases Kcat).  However, this kind of mutation leaves the PTP resistant to regulation by 
reversible oxidation.  In D/S mutants, the aspartate residue 181, the catalytic quench, is mutated 
to an alanine residue, allowing the PTP to bind to its physiological substrate in the cell, but 
unable to dephosphorylate it and release the substrate.  In contrast to the C/S substrate trapping 
mutant, the D/A mutant retains the sensitivity of the catalytic cysteine to oxidation.  The Kcat of 
the D/A mutant is severely decreased without substantially affecting the ability of the enzyme to 
bind to its substrate (Km) (Blanchetot et al., 2005; Flint et al., 1997a). 
ESP 
ESP, or osteotesticular protein tyrosine phosphatase (OST-PTP), belongs to the class of 
classical receptor protein tyrosine phosphatases.  It contains two phosphatase domains with a 
catalytically inert second domain (CD2).  Expressed predominantly in the osteoblasts and Sertoli 
cells of the testis, ESP was postulated to be involved in osteoblast function for three reasons: its 
expression is upregulated by parathyroid hormone, ex vivo differentiation of rodent calvaria-
derived osteoblasts increases its expression, and targeted knockdown of ESP results in 
abrogation of primary osteoblast differentiation (Mauro et al., 1996; Mauro et al., 1994) 
(Chengalvala et al., 2001; Dacquin et al., 2004).  
 In vivo during embryonic skeletogenesis, ESP expression is regulated temporally and 
spatially.  At E12.5 its expression is detectable in the mesenchyme regions of cartilage and the 
craniofacial bones, ribs, limbs. From E14.5 to birth, expression becomes more localized to the 
bone collar of skeletal elements undergoing endochondral ossification and the skull regions of 
intramembranous ossification.  At this point in development, ESP expression is excluded from 
regions of developing cartilage (Yunker et al., 2004).  In the bone collar of long bone, the 
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expression of ESP colocalizes with osteoblast markers Runx2 and Col1a1.  In adult mice, ESP 
expression remains in the bone collar (Dacquin et al., 2004). 
The expression of ESP in differentiating primary osteoblasts in the developing skeleton 
suggests that its role may be crucial for ossification and/or bone mass accrual.  However, mice 
lacking Esp do not possess a skeletal or bone formation phenotype.  Instead, they are defined by 
increased osteocalcin activity as a result of enhanced insulin signaling in the osteoblasts (Figure 
1-6) (Ferron et al., 2010a; Lee et al., 2007). 
By directly binding to, and dephosphorylating the insulin receptor in osteoblasts, ESP 
regulates the osteoblast expression of Osteoprotogerin to promote osteoclast maturation and the 
expression of osteoclast genes necessary for acidification of the resorption lacunae. Thus, 
through a triple inhibition pathway, ESP negatively regulates activity of osteocalcin and whole 
body glucose metabolism (Ferron et al., 2010a).  As a result, Esp-/-, as well as Esposb-/- (generated 
using Col1a1-Cre,) mice display marked hypoglycemia and hypoinsulinemia that is detected 
soon after birth and persists into adulthood.  Glucose tolerance test and insulin tolerance tests 
indicate that Esp-/- mice have increased glucose tolerance as well as insulin sensitivity as a result 
of increased osteocalcin bioactivity (Lee et al., 2007). 
ESP activity is regulated by at least two factors, the sympathetic tone and the osteoblast 
transcription factor ATF4.  Its expression is dependent upon the β2-adrenergic receptor in 
osteoblasts, and accordingly, activated by the agonist isoproterenol (Yoshizawa et al., 2009).  A 
decrease in Esp expression in osteoblasts, accompanied by the resulting increase osteocalcin 
levels, accounts for the increase in glucose tolerance observed in Atf4-/- mice (Hinoi et al., 2008). 
However, ESP function is not evolutionarily conserved.  Human ESP codes a shorter 
protein than mouse ESP, with which it shares 58% sequence identity.  It lacks 12 exons and 
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several critical residues from its first phosphatase domain, including some within the PTP 
signature motif.  This finding identifies ESP as the only class I classical protein tyrosine 
phosphatase that does not have a functional human homologue, and studies suggest that its 
function in murine osteoblasts does not extend to humans (Cousin et al., 2004b). 
Instead, PTP1B replaces ESP function in human osteoblasts.  PTP1B is expressed in the 
osteoblast and has been shown to bind to the human osteoblast insulin receptor in vitro. 
Interestingly, PTP1B is present at higher levels in human versus mouse osteoblasts, suggesting 
that its role in osteoblasts may be of more importance in human (Ferron et al., 2010a). 
PTP1B 
PTP1B (encoded by the gene Ptpn1) is a classical non-receptor protein tyrosine 
phosphatase that is a bona fide regulator of insulin receptor phosphorylation (Seely et al., 1996).  
Its C-terminus contains a predominantly hydrophobic domain that targets PTP1B to the 
cytoplasmic region of the endoplasmic reticulum so that it interacts with the insulin receptor 
upon its internalization. 
To address whether this phosphatase is necessary to attenuate insulin action, mice lacking 
PTP1B were analyzed for their glucose response and insulin sensitivity.  At 7-8 weeks of age, 
Ptpn1-/- mice display increased whole-body glucose tolerance and insulin sensitivity.  These   
mice had decreased body weight and adiposity and were resistant to changes brought on by a 
high fat diet – they maintained body weight, adiposity, glucose, and insulin levels close to those 
of wild-type animals on a regular diet (Elchebly et al., 1999; Klaman et al., 2000). 
Deletion of Ptpn1 results in increased phosphorylation of the insulin receptor kinase 
domain specifically on tyrosines 1146, 1150, and 1551 in the muscle and liver, but not of white 
adipose tissue.  These studies suggested PTP1B regulates whole body glucose homeostasis and 
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insulin sensitivity through regulation of insulin receptor phosphorylation in the insulin-
responsive tissues of the muscle and liver (Elchebly et al., 1999; Klaman et al., 2000). 
Thus, Ptpn1-specific deletions in the liver and muscle (using Albumin-Cre and MCK-Cre, 
respectively) were generated to confirm that PTP1B functions in these tissues to regulate glucose 
homeostasis.  Both Ptpn1liver-/-  and Ptpn1muscle-/- mice both display increased glucose tolerance 
(Zabolotny et al., 2008).  Ptpn1muscle-/- mice also display an increase in insulin sensitivity, as 
demonstrated by the insulin tolerance test and increased insulin receptor phosphorylation in these 
mice (Delibegovic et al., 2007a).  Neither of these mice, however, displayed differences in 
adiposity or body weight change.   
The same analysis was performed for Ptpn1adipose-/- using Adiponectin-Cre and aP2-Cre.  
However, these mice, whether on a normal or high fat diet, did not exhibit any changes in body 
weight or adiposity (Bence et al., 2006b).  The only significant difference in these mice was the 
size of their white adipocytes, which were significantly larger than normal, suggesting a possible 
role for PTP1B in lipogenesis.  However, this change is not correlated with an increase in insulin 
signaling, suggesting that PTP1B regulates lipogenesis through an alternate pathway. This data 
demonstrated that PTP1B does not regulate whole body adiposity and weight through its 
expression in the white adipose (Owen et al., 2012). 
The regulation of body weight and adiposity may instead rely on PTP1B actions in the 
brain, specifically in the POMC-neurons and neurons expression the leptin receptor.  Deletion of 
PTP1B in the whole brain by Nestin-Cre recapitulated the body weight and adiposity observed in 
the total knockout, coupled with an increase in energy expenditure.  In addition, these mice have 
increased leptin sensitivity, glucose tolerance, and insulin sensitivity.  However, unlike that of 
the total knockout, Ptpn1nes-/- mice have increased leptin levels (Bence et al., 2006b).  This 
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function of PTP1B was dissected further by the generation of Ptpn1 deletions in the POMC and 
leptin receptor-expression neurons of the brain. Ptpn1POMC-/- mice have both decreased adiposity 
and body weight, while Ptpn1LepR-/- mice display decreased body weight (they demonstrate 
decreased adiposity only under high fat diet conditions) (De Jonghe et al., 2011; Tsou and Bence, 
2012; Tsou et al., 2012).  These results suggest that PTP1B functions in this region of the brain 
to regulate leptin sensitivity and energy expenditure, thus affecting body weight and adiposity.   
TC-PTP 
Sharing 74% catalytic domain (72% identity, 86% similarity) homology with PTP1B, T-
cell protein tyrosine phosphatase (TC-PTP, encoded by the gene Ptpn2) is a non-receptor 
classical PTP that exists in two isoforms.  The longer, 48-kDa form (TC48) is restricted to the 
ER while the 45-kDa (TC45) form, which lacks the hydrophobic C-terminus, is localized to the 
nucleus.  Though TC-PTP exists mainly as TC45, it has been demonstrated that its localization is 
not limited to the nucleus, and that TC45 can shuttle between the nucleus and cytoplasm.  In 
response to insulin stimulation, TC45 exits the nucleus where it accumulates in the cytoplasm to 
interact with the internalized insulin receptor to attenuate its phosphorylation (Galic et al., 2003).  
Single nucleotide polymorphisms (SNPs) in human PTPN2 have been associated with 
susceptibility for the development of type 1 diabetes, Crohn’s disease, rheumatoid arthritis, and 
juvenile idiopathic arthritis (Espino-Paisan et al., 2011; 2007; Smyth et al., 2008; Thompson et 
al., 2010). 
            Due to its function in immune homeostasis, mice that lack TC-PTP develop systemic 
inflammatory disease and do not survive past 5 weeks of age (You-Ten et al., 1997).  During this 
time, they display growth retardation, splenomegaly, lymphadenopathy and an inability to 
respond to mitogens and T-cell dependent B-cell responses.  These mice have increased 
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mononuclear infiltrates and cytokine production in the liver and salivary gland, which leads to 
tissue damage and their eventual death (Heinonen et al., 2004).  TC-PTP function has been 
somewhat elucidated in T-cells, where TC-PTP directly binds to and dephosphorylates Src 
family kinases to regulate T cell activation and proliferation (Wiede et al., 2011).  Mice lacking 
Ptpn2 specifically in T-cells develop whole-body inflammation and autoimmunity (Heinonen et 
al., 2004).   
 Due to their growth defects, Ptpn2-/- mice have smaller skeletons with decreased 
vertebrate and femoral length.  They also display higher levels of bone resorption, coinciding 
with significantly larger osteoclasts.  Ptpn2-/- bone-marrow osteoclast precursors grown ex vivo 
in the presence of M-CSF and RANKL also develop into larger osteoclasts, suggesting that TC-
PTP regulates osteoclast fusion and/or maturation cell-autonomously.  The Ptpn2 knockout 
skeletal phenotype is somewhat strain-dependent, as mice on a BALB/c background had smaller 
skeletons with increased trabecular bone volume.  On a C57BL/6 background, the skeletons 
displayed no difference in trabecular bone volume and lifespan was increased (Doody et al., 
2012).   
            The early lethality of Ptpn2-/- prevents analysis of its role in whole body metabolism. Yet 
Ptpn2+/- mice survive and display no obvious abnormalities.  Their body weights are similar to 
those of their wild-type littermates, suggesting that one allele of Ptpn2 is sufficient to normalize 
cytokine production and the inflammatory response.  Though they display normal glucose 
tolerance and insulin sensitivity, mice lacking one allele of Ptpn2 have decreased liver glucose 
output.  Lack of one allele of Ptpn2 also imparts protection from high fat diet induced 
hyperglycemia.  In the hepatocytes isolated from Ptpn2+/- mice, both Y1162/Y1163 insulin 
receptor and IL-6 induced STAT3 phosphorylation were increased, coinciding with decreased 
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expression of the gluconeogenic genes G6pc and Pck1.  This suggests that TC-PTP regulates 
insulin signaling in the liver in vivo (Fukushima et al., 2010). 
            To assess the role of TC-PTP in the muscle, Ptpn2muscle-/- mice were generated using a 
floxed allele of Ptpn2 crossed to MCK-Cre.  These mice displayed no difference in insulin 
signaling in the muscle, and thus conferred no alternations in glucose homeostasis.  This held 
true even when Ptpn2muscle-/- mice were challenged on a high fat diet, suggesting that TC-PTP 
does not impart its regulation of the insulin receptor in muscle cells	  (Loh et al., 2012). 
It has been demonstrated that levels of TC-PTP were increased in the hypothalamus upon 
leptin treatment or diet-induced hyperleptinemia, suggesting that TC-PTP regulates leptin 
signaling or is regulated by leptin signaling.  To elucidate the function of TC-PTP in the brain, 
Ptpn2Neuron-/- mice were generated using Nestin-Cre.  The administration of leptin resulted in 
increased STAT3 Y705 in the hypothalamus, coinciding with increased expression of STAT3 
gene targets Pomc and Agrp.  Using overexpression and knockdown analysis of TC-PTP in 
Chinese hamster ovary (CHO) cells, Koh et al. demonstrated that TC45 regulates leptin-induced 
STAT3 Y705 phosphorylation.  Expression of the substrate-trapping mutant (TC45-D182A) 
results in nuclear accumulation of Y705-phosphorylated STAT3, supporting the notion that 
TC45 acts on STAT3 in the nucleus (Loh et al., 2011a).   
Ptpn2Neuron-/- mice were approximately 20% smaller, coinciding with decreased growth 
hormone and IGF-1 levels, decreased food intake, and increased energy expenditure.  They 
displayed increased glucose tolerance and insulin sensitivity with reduced fasted glucose and 
insulin levels.  Lack of TC-PTP in neuronal cells confers a resistance to diet-induced obesity 






Figure 1-1. A schematic representation of the transcriptional control of the chondrocyte 
and osteoblast lineages  Regulation at the transcriptional level is displayed in blue, while 
regulation at the post-transcriptional level is shown in green.  Red asterisks indicate genes that 







Figure 1-2. Crystal structure of Ebf1 dimer bound to DNA from two different views.  A. β 
strands of the DNA binding domains (DBDs) bound to DNA.  B. Aerial view of the dimers, 




Figure 1-3. The multinucleated osteoclast forms an acidic lacuna that facilitates the 






Figure 1-4. Molecular mechanisms regulating osteoclast differentiation.  Figure adapted 












Figure 1-5. The RANKL/OPG/RANK system.  Osteoblasts secrete OPG, is a soluble RANK 








Figure 1-6.   Insulin signaling in the cell activates uptake of glucose, amino acids, and free 
fatty acids.  Figure from (Saltiel and Kahn, 2001). 
Phosphotidylinositol-3-phosphates regulate three main classes of
signalling molecules: the AGC family of serine/threonine protein
kinases34, guanine nucleotide-exchange proteins of the Rho family of
GTPases35, and the TEC family of tyrosine kinases36. PI(3)K also acti-
vates the mTOR/FRAP pathway, and might be involved in regulation
of phospholipase D, leading to hydrolysis of phosphatidylcholine and
increases in phosphatidic acid and diacylglycerol. The best character-
ized of the AGC kinases is phosphoinositide-dependent kinase 1
(PDK1), one of the serine kinases that phosphorylates and activates
the serine/threonine kinase Akt/PKB37. Akt possesses a PH domain
that also interacts directly with PtdIns(3,4,5)P3, promoting 
membrane targeting of the protein and catalytic activation. Akt has
been suggested to be important in transmission of the insulin signal,
by phosphorylation of the enzyme GSK-3 (see below), the forkhead
transcription factors and cAMP response element-binding 
protein38,39. Although studies using inhibitory or activated forms of
Akt have not uniformly inhibited or mimicked insulin actions40,
deletion of Akt2 produces hepatic insulin resistance in mice41. Other
AGC kinases that are downstream of PI(3)K include serum- and glu-
cocorticoid-regulated kinase and the atypical PKCs, PKC-! and -"42.
Akt and/or the atypical PKCs seem to be required for insulin-
stimulated glucose transport. 
Activity of this pathway is also determined by phosphatidylinosi-
tol-3-phosphates such as phosphatase and tensin homologue43 and
the SH2 domain-containing inositol-5-phosphatase SHIP2 (ref. 44).
Overexpression of these enzymes leads to decreased levels of
PtdIns(3,4,5)P3. This might terminate signal transduction and/or
change the nature of the phosphoinositides, altering the binding
specificity to PH or phox homology domains. Disruption of these
genes or reducing expression of these messenger RNAs yields mice
with increased insulin sensitivity45. 
The CAP/Cbl pathway and lipid rafts
In addition to PI(3)K activity, other signals seem to be required for
insulin-stimulated glucose uptake10. This second pathway appears to
involve tyrosine phosphorylation of the Cbl protooncogene46. In
insight review articles
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Figure 2 Signal transduction in insulin
action. The insulin receptor is a tyrosine
kinase that undergoes
autophosphorylation, and catalyses the
phosphorylation of cellular proteins such
as members of the IRS family, Shc and
Cbl. Upon tyrosine phosphorylation, these
proteins interact with signalling molecules
through their SH2 domains, resulting in a
diverse series of signalling pathways,
including activation of PI(3)K and
downstream PtdIns(3,4,5)P3-dependent
protein kinases, ras and the MAP kinase
cascade, and Cbl/CAP and the activation
of TC10. These pathways act in a
concerted fashion to coordinate the
regulation of vesicle trafficking, protein
synthesis, enzyme activation and
inactivation, and gene expression, which














Figure 1 The regulation of metabolism
by insulin. Insulin is the most potent
anabolic hormone known, and promotes
the synthesis and storage of
carbohydrates, lipids and proteins, while
inhibiting their degradation and release
into the circulation. Insulin stimulates the
uptake of glucose, amino acids and fatty
acids into cells, and increases the
expression or activity of enzymes that
catalyse glycogen, lipid and protein
synthesis, while inhibiting the activity or
expression of those that catalyse
degradation.




Figure 1-7.  Bone activation of osteocalcin activity.  Insulin signals to the osteoblast, 
repressing Opg expression and the activation of osteoclast maturation.  Mature osteoclasts form 
an acidic resorption lacuna that facilitates the release and decarboxylation of osteocalcin, which 
when released into circulation, promotes insulin secretion in the pancreas.  Figure from (Ferron 











Figure 1-8. The protein tyrosine phosphatase catalytic mechanism. The first step of catalysis 
involves nucleophilic attack of the phosphorylated substrate and transfer of the phosphotyrosyl 
group to the PTP.  The substrate is thus released.  In the second step, the phosphotyrosyl group is 






Figure 1-9. A model of protein tyrosine phosphatase activity. Ligand binding activates an 
NAD-dependent oxidase, which reversibly oxidizes the catalytic cysteine of an active PTP.  
Inactivation of the PTP thus allows phosphorylation of the RTK substrate and signalling to 
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Early B-cell factor 1 (Ebf1) is a transcription factor whose inactivation in all cells results in high 
bone mass because of an increase in bone formation.  This observation suggests Ebf1 may be an 
inhibitor of osteoblast differentiation.  To test this contention, we analyzed Ebf1 pattern of 
expression and function in osteoblasts in ex vivo and in vivo through osteoblast-specific 
inactivation in in the mouse.  We show here that in vivo deletion of Ebf1 in osteoblast 
progenitors does not affect osteoblast differentiation or bone formation accrual post-natally.  







 Our understanding of the transcriptional control of the differentiation processes that 
generate, during embryonic development, the various cell types of mesenchymal origin, i.e. the 
osteoblast, chondrocyte, myoblast, and adipocyte, has made considerable progress during the 
past two decades.  Although these cell types derive from a common progenitor, the mesenchymal 
stem cell (MSC), their differentiation along various lineages depends on distinct sets of 
transcription factors.  In particular, the early steps of differentiation of MSCs to osteoblasts 
require the function of Runx2, while later steps of differentiation involve at least two other 
transcription factors, Osterix and Atf4 (Karsenty et al., 2009).  
 Besides the cardinal transcription factors mentioned above, many others have been shown 
to affect osteoblast differentiation either by modulating Runx2 activity or by functioning 
independently of Runx2.  Twist and Schnurri-2 are two examples of the former (Bialek et al., 
2004; Jones et al., 2007), while members of the AP-1 family and Creb act independently of 
Runx2 to affect osteoblast differentiation and proliferation (Bozec et al., 2010; Kajimura et al., 
2011).  Another factor for which mouse genetics has given clear indications that it contributes to 
osteoblast phenotype is Ebf1. 
 Early B-cell factor 1 (Ebf1) is a member of a small family of transcription factors that 
contains an atyptical zinc finger DNA binding domain and a non-basic helix-loop-helix (HLH) 
dimerization domain (Hagman et al., 1993).  Originally cloned as a putative B-cell transcription 
factor, Ebf1 was confirmed by loss-of-function experiments in the mouse to be a pioneer factor 
essential for the commitment and maintenance of B-cell fate (Gyory et al., 2012; Hagman et al., 
1993).  The cell differentiation ability of Ebf1 has been expanded to neurons of the embryonic 
striatum during mouse development (Garel et al., 1999).  More recently, two indirect but 
61 
	  
convergent lines of evidence raised the prospect that Ebf1 may prevent osteoblast differentiation 
and instead favor allocation of MSCs toward the adipocyte lineage.  First, in the pre-adipogenic 
3T3L1 cell line Ebf1 promotes PPARγ expression, while reducing Ebf1 expression inhibits the 
adipocyte differentiation potential of this cell line (Akerblad et al., 2002; Jimenez et al., 2007).  
Second, and more importantly for our purpose, analysis of mice lacking Ebf1 in all cells revealed 
a marked increase in the number of osteoblasts and in bone formation parameters (Fretz et al., 
2010; Hesslein et al., 2009).  This experiment established that Ebf1 as a negative regulator of 
osteoblast differentiation.  As importantly, that this high bone mass phenotype was observed in 
mice lacking Ebf1, but not other members of this small family of transcription factors, indicated 
that there was no overt redundancy between Ebf1 and other members of the Ebf family when it 
comes to the regulation of osteoblast differentiation.   
 In view of the strong phenotype of Ebf1-/- mice and of Ebf1 differentiation ability in other 
cell lineages, it is legitimate to suspect that Ebf1 inhibits osteoblast differentiation in a cell-
autonomous manner.  To determine if this is indeed the case we relied on Ebf1 knockdown in 
cell culture and the analysis of mutant mice lacking Ebf1 only in cells of the osteoblast lineage.  
To our surprise, Ebf1 deletion in cells of the osteoblast lineage throughout development and after 
birth has no overt deleterious consequences on the differentiation of osteoblasts, bone formation 
parameters, or overall bone mass accrual.  Taken at face value, these observations identify Ebf1 





Materials and Methods 
Mice Generation. Ebf1fl/+mice were generated as previously described (Treiber et al., 2010b).  
To generate osteoblast-specific Ebf1 deficient mice, Ebf fl/fl mice were crossed with Runx2- Ebf1 
fl/+;Cre mice, which were then crossed to Ebf fl/fl mice to generate Ebf1osb-/- mice. Genotypes of 
mice were determined by PCR.  Primer sequences are available upon request.  All mice were 1-
month old males maintained on the C57BL/6 genetic background.   
In situ hybridization. Embryos were fixed in 4% paraformaldehyde and embedded in paraffin.  
Radioactive in situ hybridization was performed on 6µm sections using 35S-labeled riboprobes. 
Hybridizations were performed overnight at 55°C, and washes were performed at 63°C. 
Autoradiography and Hoechst 33528 staining were performed as described (Ducy and Karsenty, 
1995).  Probe sequences available upon request.   
Molecular Studies. RNA isolation and quantitative PCR were performed following standard 
protocols.   
Statistical Analysis. Results are given as means ± standard error of means unless otherwise 
indicated. Statistical analyses were performed using the Student's t-test 
Cell Culture. Primary osteoblasts were cultured and differentiated as previously described 
(Ducy et al., 2000).  Cells were transfected with siRNA pools (on-TARGETplus SMARTpool, 
Dharmacon) according to manufacturer instructions.  Ebf1+/+ or Ebf1−/− osteoblasts were 
generated by infecting Ebf1fl/fl osteoblasts with either green fluorescent protein (GFP)- or Cre-
expressing adenovirus (University of Iowa) 
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Chromatin Immunoprecipitation (ChIP). Target cells were harvested and resuspended in 
medium at a concentration of 1 to 2x10^6 cells/ml. Crosslinking mix (11%% formaldehyde, 
100mM NaCl, 0.5mM EGTA, 1mM EDTA, 50mM Hepes pH 8.0) was added to a final 
concentration of 1% formaldehyde. Crosslinking reaction was stopped after 10min at room 
temperature by the addition of glycine to a final concentration of 125mM. Cells were spun down 
immediately and washed three times with ice cold PBS. They were resupended in lysis buffer 
(1.25% SDS, 12.5 mM EDTA, 62.5mM Tris-HCl pH 8.0, protease inhibitor mix) with a 
concentration of 20 to 40x10^6 cells/ml. With a Bioruptor® Standard the chromatin was sheared 
into pieces of 300 to 500 bp. This chromatin was stored at -80°C and subsequently used for ChIP 
experiments. 
For each ChIP 100µl chromatin were diluted 1/10 in dilution buffer (50mM Tris-HCl pH 8.0, 
5mM EDTA, 200mM NaCl, 0.5% NP-40, protease inhibitor mix). 4µg of an anti-murine Ebf1 
antibody (noncommercial polyclonal rabbit anti Ebf1 antibody, protein G purified) or normal 
rabbit IgG (Millipore 12-370) was added. Samples were rotated for 16-20 hours at 4 °C and 
washed Protein-A Sepharose beads were added for another two hours. Subsequently beads were 
washed five times with wash buffer (0.1% SDS, 1% NP-40, 2mM EDTA, 500mM NaCl, 20mM 
Tris-HCl pH 8.0) and four times with TE buffer (10mM Tris-HCl pH8, 1mM EDTA pH8.0). 
Immunoprecipitated chromatin was eluted two times with 50µl elution buffer (2%SDS, 10mM 
Tris-HCl pH8, 1mM EDTA pH8.0) for 10min at 65°C shaking. Elutions were pooled and 
decrosslinked for at least six hours at 65°C. DNA was finally purified with QIAquick® PCR 
Purification Kit (Qiagen Cat.No.28106). The purified DNA was used in quantitative PCR to 
analyze binding of Ebf1 to DNA. 
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Histology.  Static and dynamic histomorphetric analyses were performed on vertebral column 
specimens collected from 1-month old mice using undecalcified sections according to standard 
protocols, and using the Osteomeasure analysis system (Osteometrics). 
Results 
Ebf1 is expressed at low levels in osteoblasts during embryonic development 
At the onset of this study to guide our investigation, we sought to determine which 
members of the Ebf family were the most highly expressed in primary osteoblasts.  qPCR 
analysis using exonic primers normalized to genomic DNA revealed that in osteoblasts, Ebf1 was 
clearly more abundantly expressed than the other three members of the Ebf family.  In cells that 
that were fully differentiated, this difference in level of expression was at least one order of 
magnitude (Fig. 2-1A).  Given this result and the important fact that deletion of Ebf1 in all cells 
in and by itself suffices to affect bone mass accrual, we thus focused the remainder of our 
analysis on the function Ebf1 may have in osteoblasts. 
 We first studied Ebf1 pattern of expression in developing skeleton by in situ 
hybridization.  As previously shown, the marker of bone formation Runx2, is robustly expressed 
in osteoprogenitors of the developing ribs already at E12.5 (Ducy et al., 1997),  In contrast, in an 
adjacent section, the expression of Ebf1 in osteoprogenitors, although detectable, was 
significantly weaker (Fig. 2-1B).  Similarly, at E14.5 and E16.5, expression of Runx2 in cells of 
the osteoblast lineage was quite high, but expression of Ebf1 remained barely above the limit of 
detection (Fig. 2-1B). Finally, we compared the expression of Ebf1 in adult tissue, and also 
observed rather low expression in bone and cartilage (Fig. 2-1C).  In summary, these results 
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indicate that Ebf1 expression does not appear as early as Runx2 and is less pronounced than the 
one Runx2 during skeletogenesis. 
Ebf1 affects osteoblast gene expression ex vivo.   
Next, to determine whether or not Ebf1 may be a cell-autonomous molecular suppressor 
of osteoblast differentiation, we analyzed the effects of siRNA-mediated down-regulation of 
Ebf1 mouse osteoblasts that were transfected with a siRNA to transiently suppress Ebf1 
expression but not affect Ebf2, 3, or 4 expression (Fig. 2-2A).   
 For that purpose, primary osteoblasts from calvaria of newborn mice were transfected 
with Ebf1 siRNA, resulting in a 76% decrease in Ebf1 expression. We also confirmed that the 
siRNA we used was specifically targeting Ebf1, and did not result in altered expression of Ebf2, 
3, or 4 (Fig. 2-2A). Ebf1 knockdown in primary osteoblasts increased expression of Osterix, 
Col1a1, Osteocalcin, and Alkaline phosphatase (Alpl).  These results were certainly consistent 
with the notion that Ebf1 acts as a cell-autonomous inhibitor of osteoblast differentiation.  Of 
note, within the conditions of this experiment, we did not observe any change in the expression 
of adipocyte-specific transcription factors such as PPARγ, C/EBPα, C/EBPβ (Fig. 2-2A).    
 In view of these results we asked whether Ebf1 directly binds to some of the genes whose 
expression was perturbed by its knockdown in the above-mentioned experiment.  We employed 
an Ebf1 chromatin immunoprecipitation (ChIP) seq analysis to identify potential Ebf1-binding 
sites, and further validated these sites by quantitative ChIP.  This analysis indicated that Ebf1 
binds at multiple sites in the Alpl and Osterix regulatory regions (Fig. 2-2B).  It is interesting to 
note that the Ebf1-bound site on the Alpl gene coincides rather well with the presence of DNase 




Ebf1-independent osteoblast differentiation in vivo 
 In view of this encouraging set of ex vivo observations, we next studied the function of 
Ebf1 specifically in osteoblasts in vivo and crossed Ebf1fl/fl mice with mice expressing Cre 
recombinase under the control of the Runx2 regulatory elements (Rauch et al., 2010).  We chose 
Runx2-Cre mice to address this question, as Runx2 is the earliest and also the most specific 
molecular marker of the osteoblast lineage identified to date (Ducy et al., 1997).  Hence, this Cre 
driver would allow us to study Ebf1 functions in cells of the osteoblast lineage at each stage of 
differentiation. Prior to analyzing these mice, we verified that we had achieved efficient deletion 
of Ebf1 in osteoblasts.  Ebf1 was decreased by 80% in whole bone, and by more than 95% in 
osteoblasts derived from bone marrow.  Although Ebf1 expression was also reduced in cartilage, 
its expression was not affected in the other tissues tested (Supplemental Fig. 2-1).   
Ebf1osb-/- mice were born at the expected Mendelian ratio, had normal life expectancy, 
and appeared overall normal, indicating that its expression in Runx2-expressing cells is 
dispensable for normal embryonic development.  Body weight, epididymal fat pad weight, body 
and femoral lengths were similar between Ebf1osb-/- mice and control littermates (Ebf1fl/+, Ebf1fl/fl, 
and Runx2-Cre mice) (Fig. 2-3A).  To our surprise, bone histomorphometric analysis performed 
in vertebrae of 1-month old Ebf1osb-/- and control mice did not reveal any change in osteoblast 
number, bone formation rate, and bone mass (Fig. 2-3B).  Serum osteocalcin levels were 
similarly unaffected in Ebf1osb-/- mice (Fig. 2-3C).  Gene expression analysis performed in bone 
tissue did not record any of the changes in gene expression that had been observed in cell culture 
experiments (Fig. 2-3D). This set of observations indicates that in vivo, Ebf1 does not regulate 
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osteoblast differentiation through its expression in cells of the osteoblast lineage even though ex 
vivo Ebf1-/- osteoblasts form less mineralization nodules and produce slightly less alkaline 
phosphatase (Fig. 2-4A and 2-4B).    
Discussion 
 Previous observations stemming from cell culture experiments and from the analysis of 
mice lacking Ebf1 in all cells had indicated that Ebf1 is a negative regulator of osteoblast 
differentiation and bone formation (Akerblad et al., 2002; Hesslein et al., 2009; Jimenez et al., 
2007).  These data immediately raised the question of whether Ebf1 acts in a cell-autonomous 
manner to fulfill this function. This is an even more important question given the fact that among 
all members of this small family of transcription factors, Ebf1 is the most highly expressed in 
cells of the osteoblast lineage by far. 
 Transient Ebf1 loss of function experiments performed in primary osteoblasts fully 
supported the notion that Ebf1 negatively regulates osteoblast-specific gene expression.  Since 
expression of important genes for the osteoblast phenotype as Osterix, Col1a1, Osteocalcin, and 
Alpl were dramatically increased in cells lacking Ebf1.  These results were fully consistent with 
the high bone mass observed in Ebf1-/- and suggested that Ebf1 acts in a cell autonomous manner 
to regulate osteoblast differentiation. 
 Hence, it came as a surprise that cell-specific Ebf1 deletion in cells of the osteoblast 
lineage in the mouse does not have any overt consequences on osteoblast differentiation in vivo. 
Results of this analysis in Ebf1osb-/- mouse model are surprising for several reasons.   
 The first reason is that the in vivo results have no clear relationship to what was 
previously observed in cell culture by others and by us, after a decrease of Ebf1 expression in 
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differentiated osteoblasts (Akerblad et al., 2002; Jimenez et al., 2007).  As such, these results 
illustrate how cautious one should be when making inference about the differentiation ability of a 
given transcription factor or of any other regulatory gene based on cell culture assays alone.  
This result was even less expected given the fact that Ebf1 binding sites are present in such an 
important regulator of osteoblast differentiation as Osterix.  Last, but not least, these results were 
also unanticipated because they are not consistent with what has been observed in mice globally 
lacking Ebf1, which display high bone mass with a concomitant decrease in adiposity (Hesslein 
et al., 2009).    
 Although the formal possibility remains that Ebf1 function is masked by the remaining 
expression of Ebfs 2, 3, and 4.  We note that mice lacking Ebf1 in all cells present cell 
differentiation defects even though other Ebfs are normally expressed.  Thus we believe this is an 
unlikely possibility (Lin and Grosschedl, 1995). At the present time the most likely interpretation 
of the unanticipated results presented here is that the phenotype observed previously in Ebf1-/- 
mice may be due to a cell-nonautonomous defect.  Hence, Ebf1 may belong to a novel class of 
transcriptional regulators of osteoblast differentiation that acts in a non-cell autonomous manner. 
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Figure 2-1. Ebf1 expression analysis. (A) Normalized expression of Ebf1, 2, 3, and 4 by qPCR 
in primary osteoblasts differentiated in culture.  (B) Expression pattern analysis of Ebf1 by 
radioactive in situ hybridization of adjacent sections featuring osteoblast (Runx2) regions in 
mouse embryos.  (C) qPCR analysis of Ebf1 expression in adult mouse tissue. Reference gene is 





Figure 2-2. Ebf1 analysis in 10T1/2 cells (A) Ebf1 siRNA knockdown in primary osteoblasts.  
n.e. not expressed.  (B) Analysis of Ebf1 direct targets in a mesenchymal cell line. Binding is 
represented as a percentage of input chromatin, and error bars represent standard deviation of 





Figure 2-3. Phenotype analysis of Ebf1osb-/-. (A) Body weight, percent gonadal fat (FPW/BW), 
body length, and femur length, (B) Bone histomorphetric analysis, (C) osteocalcin measurement 






Figure 2-4. Differentiated primary osteoblasts persistently lacking Ebf1 by (A) von Kossa, 




Supplementary Figure 2-1. Deletion of the Ebf1 allele in indicated tissues and in primary 





Chapter Three: T-Cell Protein Tyrosine Phosphatase (TC-PTP) Regulates 
Bone Resorption and Whole-Body Insulin Sensitivity Through Its Expression 
in Osteoblasts 
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Insulin signaling in osteoblasts contributes to whole body glucose homeostasis in the mouse and 
in humans by increasing the activity of osteocalcin.  The osteoblast insulin signaling cascade is 
negatively regulated by ESP, a tyrosine phosphatase dephosphorylating the insulin receptor. Esp 
is one of many tyrosine phosphatases expressed in osteoblasts, and this observation suggests that 
other protein tyrosine phosphatases may contribute to the attenuation of insulin receptor 
phosphorylation in this cell type.  In this study, we sought to identify additional PTP(s) that like 
ESP, would function in the osteoblast to regulate insulin signaling and thus affect activity of the 
insulin-sensitizing hormone osteocalcin.  For that purpose, we used as criteria, expression in 
osteoblasts, regulation by isoproterenol, and ability to trap the insulin receptor in a substrate-
trapping assay.  Here we show that the T-cell protein tyrosine phosphatase (TC-PTP) regulates 
insulin receptor phosphorylation in the osteoblast, thus compromising bone resorption and 
bioactivity of osteocalcin.  Accordingly, osteoblast-specific deletion of TC-PTP promotes insulin 
sensitivity in an osteocalcin-dependent manner.  This study increases the number of genes 




The tenuous cross-talk existing between bone remodeling and energy metabolism was 
first demonstrated in vivo through the realization that leptin, an adipocyte-derived hormone, 
inhibits both appetite (Flier and Elmquist, 1997; Friedman and Halaas, 1998; Spiegelman and 
Flier, 2001) and bone mass accrual (Ducy et al., 2000). The existence of this crosstalk was then 
further substantiated by the observation that in turn, osteoblasts regulate whole-body glucose 
metabolism, through secretion of the hormone osteocalcin that favors insulin secretion, insulin 
sensitivity, and increases energy expenditure (Ferron et al., 2008; Lee et al., 2007; Rached et al., 
2010a).   
Like other peptide hormones, osteocalcin undergoes significant post-translational 
modifications before being released into the general circulation (Hauschka et al., 1989b; Steiner, 
2011).  Specifically, osteocalcin, which is secreted by osteoblasts as a γ-carboxylated protein, 
must be decarboxylated to become activated and able to fulfill its endocrine functions (Lee et al., 
2007).  This activation of osteocalcin has been shown to occur outside the osteoblast, in the bone 
resorption lacunae (Ferron et al., 2010a).  As the only mechanism known to decarboxylate 
proteins outside of the cell is by incubating them in an acidic pH, the passage of osteocalcin 
through the acidic microenvironment of the resorption lacunae allows it to become 
decarboxylated and thus activated (Engelke et al., 1991; Ferron et al., 2010a). In effect, the 
resorbing function of osteoclasts favors glucose homeostasis by activating osteocalcin (Ferron et 
al., 2010a).   
In addition to being an endocrine cell, the osteoblast receives many endocrine signals, 
one of them being insulin.  Among other functions, insulin signaling in osteoblast inhibits the 
expression of Opg, a gene encoding a decoy receptor for the RANKL osteoclast differentiation 
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factor.  As a consequence, insulin signals to the osteoblast to promote bone resorption, 
osteocalcin bioactivity, and thereby its own secretion (Ferron et al., 2010a).    
As it is the case in other insulin sensitive cells such as in the hepatocytes and myocytes, 
the insulin signaling cascade in the osteoblast is tightly regulated (Saltiel and Kahn, 2001; 
Schlessinger, 2000; Tonks, 2006).   In particular, protein tyrosine phosphatases (PTPs) play a 
crucial role in attenuating insulin receptor phosphorylation to limit insulin signaling in many cell 
types and maintain glucose homeostasis (Hunter, 1995; Schlessinger, 2000; Tonks, 2006).  To 
date, the only tyrosine phosphatase expressed in the mouse osteoblast that has been shown to 
dephosphorylate the insulin receptor is ESP (Ferron et al., 2010a).  As a result, the deletion of 
Esp specifically in the osteoblast enhances insulin signaling, increases circulating levels of active 
osteocalcin, and accordingly, favors glucose tolerance, insulin sensitivity, and energy 
expenditure (Ferron et al., 2010a; Lee et al., 2007).  This and other experiments have identified 
ESP as a major intracellular regulator of osteocalcin’s endocrine function in the mouse. 
However, ESP is not the only PTP present in osteoblasts, an observation suggesting that 
other PTPs in addition to ESP might contribute to the regulation of glucose metabolism through 
their expression in osteoblasts.  If this were the case, it would strengthen the notion that bone is 
involved in the regulation of glucose metabolism. 
To address this question, and since ESP belongs to the family of classical PTPS, which 
are defined by their specificity for phosphotyrosine (Alonso et al., 2004; Barr et al., 2009), we 
tested all 37 other mammalian classical PTPs for their ability to bind to the endogenous insulin 
receptor in osteoblasts and to be up-regulated by isoproterenol, as is Esp (Hinoi et al., 2008).  
Only one PTP was able to bind to the osteoblast insulin receptor and respond to isoproterenol 
treatment – TC-PTP.  We show here that TC-PTP regulates osteocalcin bioactivity by inhibiting 
81 
	  
bone resorption, thus affecting whole-body glucose metabolism.  Hence, these results identify a 




All mice studied were age-matched littermate males on a mixed (87.5% C57BL/6J; 
12.5% 129/Sv) background. Genotyping was performed by PCR using DNA extracted from tail 
tips; primer sequences are available upon request.  All mice were maintained on a 12-hour 
light/dark cycle in a barrier facility with free access to standard chow and water, and analyzed at 
5-7 weeks of age. 
Metabolic Measurements 
  Glucose in tail blood was measured using a glucometer (Accucheck).  For the glucose 
tolerance test (GTT), mice were fasted overnight and injected with 2 kg D-glucose per kg body 
weight.  Blood glucose was assayed immediately before and at 15, 30, 60, and 120 minutes post-
injection. For the insulin tolerance test (ITT), mice were fasted for 4 hours and injected with 0.5 
U/kg insulin (Humulin R, Lilly).  Blood glucose was measured immediately before and at 30, 60, 
90, and 120 minutes post-injection.  For the glucose stimulated insulin secretion (GSIS), mice 
were fasted overnight and injected with 2 kg D-glucose per kg body weight.  Tail blood was 
collected immediately before and at 2, 5, 15, and 30 minutes post-injection (Lee et al., 2007).  
ELISA were used to determine serum insulin (Mercodia), serum CTx (Serum Crosslaps, IDS), 
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and serum GLU, GLA, and total osteocalcin as previously described (Ferron et al., 2010b).  
Whole calvaria was collected in mice injected through the inferior vena cava after overnight 
fasting.  Quantification of western blot was performed using ImageJ.  
Substrate trapping and Coimmunoprecipitation 
 GST-PTPDA proteins were generated by cloning the non-receptor PTPs and cytoplasmic 
phosphatase domains of the receptor PTPs into the BamHI site of pGEX 4T3.  Site directed 
mutagenesis was used to mutate the catalytic aspartate acid residue to inactive alanine, as 
previously described (Flint et al., 1997b).  The expression vectors were then transformed into 
BL21 (DE3) pLysS bacteria (Novagen).  Recombinant GST-PTPDA proteins were induced and 
purified using glutathione-sepharose beads and then immediately incubated in lysate of 
pervanadate treated ROS17/2.8 cells, as previously described (Ferron et al., 2010a).  The proteins 
were resolved on SDS-PAGE followed by western blot.  Anti-IRβ  and anti-pTyr were obtained 
from Cell Signaling Technology.  For coimmunoprecipitation assays, PTP1B and TC-PTP and 
their respective substrate trapping mutants were cloned into the EcoRI and BamHI site of the 
pFLAG-5a expression vector.  ROS17/2.8 cells were transfected with FLAG-fusion protein or 
empty vector and InsR expressed in pCNDA3.1 using Lipofectamine 2000.   24 hours post-
transfection, FLAG-fusion protein were immunoprecipitated overnight and eluted as previously 
described (Ferron et al., 2010a) and resolved on SDS-PAGE followed by western blot.  Anti-
FLAG M2 affinity gel and 3X FLAG peptide was obtained from Sigma. 
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Cell Culture  
Mouse primary osteoblasts were isolated as previously described (Ducy et al., 1997).  
siRNA knockdown was achieved by transfection with siRNA pools (On-target, Dharmacon) 
according to manufacturer instructions.  Anti-Y1150/Y1151 IRβ antibody was obtained from 
Cell Signaling Technology.  Ptpn2+/+ or Ptpn2-/- osteoblasts were generated by infecting 
Ptpn2flox/flox osteoblasts with either GFP- or Cre-expressing adenovirus (University of Iowa).  For 
the stimulation with isoproterenol and analysis of mineralized osteoblasts, cells were 
differentiated 3 days post-confluence in α-MEM medium containing 10% FBS, 10mM β-
glycerophosphate, and 100µg/mL ascorbic acid.  Osteoblasts differentiated for 5 days were 
stimulated with isoproterenol for 4 hours.  Osteoblast/osteoclast cocultures were prepared as 
previously described (Ferron et al., 2010a).  In vitro resorption activity of osteoclasts was 
measured using BD Biocoat Osteologic Bone Cell Culture System according to manufacturer’s 
instructions.  Primary osteoblasts mineralization was visualized using Von Kossa staining and 
quantified by ImageJ.   
Gene Expression Analysis 
RNA isolation, cDNA preparation, and qPCR analysis was performed using standard 
protocols and relative Ct values are standardized to Ct  values of control β-actin or S18 (for 
osteoclasts). Exonic qPCR primers used to compare expression were normalized on                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             




Static and dynamic histomorphometric analyses were performed on vertebral column 
specimens collected from 7-week old mice using undecalcified sections according to standard 
protocols using the Osteomeasure analysis system (Osteometrics). 
Statistics 
Results are given as means ± standard errors of the mean.  Statistical analyses were 
performed using unpaired, two-tailed Student’s t-test.  For all experiments, *p ≤ 0.05, **p ≤ 
0.01, ***p ≤ 0.001. 
Results 
TC-PTP and PTP1B bind to the insulin receptor in osteoblasts 
 With the goal of identifying additional protein tyrosine phosphatases that could 
dephosphorylate the insulin receptor in osteoblasts, we tested members of the classical protein 
tyrosine phosphatase (PTP) family for in vitro binding of the insulin receptor and expression in 
osteoblasts.   
For the first purpose, we generated substrate-trapping mutants of all PTPs by introducing 
a DA substitution mutation in each phosphatase domain that abolishes catalytic activity but 
preserves the ability of the PTPs to bind substrate(s) (Blanchetot et al., 2005; Flint et al., 1997b).  
These mutant GST-fusion proteins were incubated with extracts from pervanadate-treated 
ROS17/2.8 osteoblast cells and then pulled down using glutathione beads.  As shown in Figure 
3-1A, Western blot analysis indicated that, in addition to ESP, five PTPs were able to interact 
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directly with the endogenous β-subunit of the insulin receptor in osteoblasts: PTP1B (Ptpn1), 
TC-PTP (Ptpn2), PTPCL (Ptpn3), PTPMEG (Ptpn4), and MEG2 (Ptpn9).  
In an effort to further narrow down our search, we relied on one particularity of the 
ESP/osteocalcin metabolic pathway.  Esp gene expression in osteoblasts is upregulated upon 
treatment of osteoblasts with the β2-adrenergic receptor agonist isoproterenol (Hinoi et al., 
2008).  We considered this response a defining feature of the osteocalcin regulation of energy 
metabolism, and thus tested whether expression of Ptpn1, Ptpn2, Ptpn3, Ptpn4, and Ptpn9 was 
affected by isoproterenol treatment of osteoblasts.  Remarkably, Ptpn2 expression was 
significantly affected by isoproterenol treatment in mineralized osteoblasts (Fig. 3-1B).  These 
results identify TC-PTP as the leading candidate to be a second PTP involved in the osteoblast 
regulation of energy metabolism. 
 To formally demonstrate that the insulin receptor is a physiological substrate of TC-PTP 
in osteoblasts, we performed coimmunoprecipitation with the TC-PTP substrate trapping mutants 
expressed in the osteoblast, using PTP1B as a positive control in this assay (Flint et al., 1997b).  
For that purpose, we transfected ROS17/2.8 osteoblast cells with flag-tagged wild-type and 
substrate-trapping mutants of PTP1B, TC-PTP or ESP.  IRβ coimmunoprecipitated with DA-
substrate trapping mutants of PTP1B, TC-PTP, and ESP while it did not with FLAG alone (Fig. 
3-1C).  Interestingly, wild-type ESP protein also exhibited binding to the insulin receptor, which 
was not detected with PTP1B and TC-PTP, suggesting that ESP can bind to the insulin receptor 
independently of its phosphatase domain (Fig. 3-1C).  These results confirm that the insulin 
receptor is a substrate of PTP1B and TC-PTP in rodent osteoblasts. 
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TC-PTP is expressed in insulin-responsive tissues, including osteoblasts 
In view of these results we then determined the level of expression of TC-PTP in bone 
cells in vivo.  Western blot and qPCR analysis confirmed the presence of mRNAs encoding TC-
PTP (Ptpn2) in isolated femur tissue, coinciding with the presence of the insulin receptor (Fig. 3-
1D, 3-1E).  When comparing the relative levels of Ptpn1, Ptpn2, and Esp expression by qPCR 
analysis using exonic primers normalized to genomic DNA, we observed that in all tissues 
tested, Ptpn2 expression exceeded that of both Esp and Ptpn1, with prominent expression in 
bone (Fig. 3-1D).  Because bone is composed of multiple cells types, we also analyzed 
expression of the PTPs in primary osteoblasts isolated from newborn calvaria.  Consistent with 
data obtained from whole bone, we observed that Ptpn2 was more highly expressed in primary 
osteoblasts than Ptpn1 and Esp (Fig. 3-1F).  Interestingly, Ptpn2 but not Ptpn1 expression was 
enhanced when osteoblasts were induced to fully differentiate in medium containing β-
glycerophosphate and ascorbic acid (Fig. 3-1F).  
Generation of mice lacking TC-PTP or PTP1B specifically in the osteoblast 
 To study the function of TC-PTP in osteoblasts in vivo, we used a cell-specific loss-of-
function strategy in the mouse and generated a floxed allele of Ptpn2 and Ptpn1 by homologous 
recombination in mouse ES cells.  For the Ptpn2 floxed allele targeting strategy, we used a 
targeting vector including the genomic sequence from exon 4 to exon 8.  Two loxP sites were 
added to flank exons 5 to 7, which contain the catalytic domain of TC-PTP (Fig. 3-2A).  In 
addition, a neomycin (NeoR) cassette flanked by two Frt sites was inserted in the intron between 
exon 6 and 7 (Fig. 3-2A).  Southern blot analysis identified the targeted Ptpn2 allele using a 5’ 
probe directed to intron 2 and a 3’ probe directed to the region containing exon 9 and a portion of 
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intron 8 (Fig. 3-2A).  The inserted NeoR cassette was subsequently removed by crossing mice 
containing the targeted allele with mice expressing Flp recombinase.  NeoR excision was 
verified by PCR analysis (Fig. 3-2A).   
  To delete TC-PTP specifically in osteoblasts (Ptpn2osb-/- mice) mice harboring the floxed 
allele of Ptpn2 were crossed with mice expressing the α1(I)collagen-Cre transgene (Dacquin et 
al., 2002).   PCR analysis confirmed that recombination of the Ptpn2 floxed allele was limited to 
bone only (Fig. 3-2B).  Ptpn2osb-/- mice were born at the expected Mendelian ratio and appeared 
phenotypically normal at birth, indicating that Ptpn2 expression in osteoblasts is dispensable for 
normal embryonic development.  
 To generate the Ptpn1 floxed allele, we used a targeting vector including the genomic 
sequence from exon 3 to exon 9, similarly to what has been done previously (Bence et al., 
2006a).  Two loxP sites were added to flank exons 6 to 8, since the catalytic domain of PTP1B is 
contained in exons 7 and 8 (Fig. 3-2A).  A neomycin (NeoR) cassette flanked by two Frt sites 
was inserted in the intron between exon 8 and 9 (Fig. 3-2A).  Southern blot analysis identified 
the targeted Ptpn1 allele using a 5’ probe directed to intron 2 and a 3’ probe directed to the 
region containing exon 9 (Fig. 3-2A).  The inserted NeoR cassette was subsequently removed by 
crossing mice containing the targeted allele with mice expressing Flp recombinase and 
confirmed by PCR analysis (Fig. 3-2B).  qPCR analysis of bone marrow derived osteoblasts 
estimated recombination efficiency of 47.3% (Fig. 3-2C). 
 Similarly to Ptpn2osb-/-, mice harboring the floxed allele of Ptpn1 were crossed with mice 
expressing the α1(I)collagen-Cre transgene (Fig, 3-2D, (Dacquin et al., 2002).  PCR and qPCR 
analysis confirmed that recombination of the Ptpn2 floxed allele was limited to bone only and at 
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approximately 53.6% efficiency (Fig. 3-2E, 3-2F).  Ptpn1osb-/- mice were also born at the 
expected Mendelian ratio and appeared phenotypically normal throughout life. 
TC-PTP regulates insulin signaling in osteoblasts 
Next we evaluated the contribution of TC-PTP in the regulation of insulin signaling in 
isolated osteoblasts, and compared it to that of PTP1B.  Primary cultures of calvarial osteoblasts 
were transfected with siRNA to suppress expression of either PTP1B or TC-PTP.  In response to 
insulin stimulation, phosphorylation of the insulin receptor on the Y1150 and Y1151 residues 
was enhanced in osteoblasts deficient specifically for TC-PTP (Fig. 3-3A).  There was no 
apparent increase in phosphorylation of the insulin receptor phosphorylation in osteoblasts 
lacking PTP1B.  However, normalization of the signal with the amount of total insulin receptor 
indicated that phosphorylation was in fact, increased nearly 2-fold in these osteoblasts, compared 
to the 5-fold increase observed in osteoblasts treated with TC-PTP siRNA(Fig. 3-3A).  We also 
observed that osteoblasts lacking either PTP1B or TC-PTP had increased basal expression of the 
insulin target gene Gsy1, though this increase reached statistical significance only in TC-PTP-
deficient osteoblasts (Fig. 3-3B).  Taken together, these results suggested that TC-PTP might 
play a more important role in regulating insulin signaling in the mouse osteoblast.   
In view of these results, we focused our subsequent work on TC-PTP and asked whether 
insulin signaling is enhanced in the osteoblasts of Ptpn2osb-/- mice. Western blot analysis of 
whole calvaria isolated after intravenous injection of 0.5 U/kg insulin revealed that insulin 
receptor phosphorylation was increased in Ptpn2osb-/- calvaria (Fig. 3-3C).  It is important to 
underline that because bone is a mixture of multiple cell types and Ptpn2 deletion is specific to 
osteoblasts only, the difference in insulin receptor phosphorylation in whole calvaria was 
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expected to be subtle.  Nevertheless, phosphorylation of the insulin receptor on Y1150 and 
Y1151 was enhanced more than 30% in the calvaria of Ptpn2osb-/- mice compared to their floxed 
littermate controls, confirming that TC-PTP regulates insulin receptor phosphorylation in vivo 
(Fig. 3-3C). 
Mice lacking TC-PTP specifically in osteoblasts demonstrate increased osteocalcin 
bioactivity and insulin sensitivity 
To test if TC-PTP or PTP1B regulates osteocalcin bioactivity, we quantified, using an 
ELISA developed in the laboratory (Ferron et al., 2010b), serum undercarboxylated osteocalcin 
(GLU13-OCN) levels in Ptpn2osb-/- and Ptpn1osb-/- mice.  Compared to their WT littermates, 
Ptpn2osb-/- mice have increased serum levels of GLU-13 OCN, though osteocalcin bioactivity 
was not significantly altered in Ptpn1osb-/- mice (Fig. 3-4A, 3-4B).  This result confirmed that the 
increase in insulin signaling in the osteoblasts lacking TC-PTP coincided with an increase in 
serum undercarboxylated, i.e., active osteocalcin (Fig. 3-4A).  This finding suggested that one 
function of TC-PTP in osteoblasts is to regulate osteocalcin bioactivity.   
 Given the influence exerted by osteocalcin on glucose metabolism (Lee et al., 2007), we 
then asked whether osteoblast-specific deletion of TC-PTP might affect whole-body glucose 
metabolism.  A glucose tolerance test (GTT) performed at 6 weeks of age revealed no difference 
in glucose tolerance in Ptpn2osb-/- mice (Fig. 3-4C).  As expected, there was similarly no 
difference in glucose tolerance of Ptpn1osb-/- mice (Fig. 3-4D). However, Ptpn2osb-/- mice 
consistently exhibited increased insulin sensitivity as measured by an insulin tolerance test (ITT) 
(Fig. 3-4E).  This effect was not observed in Ptpn1osb-/- mice (Fig. 3-4F).  The increase in insulin 
sensitivity of Ptpn2osb-/- mice was also apparent when calculated as the area under the curve of 
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the insulin tolerance test (Fig. 3-4G).   To test whether glucose homeostasis was altered in the 
insulin-sensitive Ptpn2osb-/-  mice under challenged conditions, we performed a glucose tolerance 
test on mice that were fed a high fat diet for 5 weeks.  Glucose tolerance was also unaffected 
under these conditions (Fig. 3-4I). These data indicated that osteoblast expression of TC-PTP but 
not of PTP1B, regulates insulin sensitivity, presumably by influencing osteocalcin bioactivity.    
A glucose stimulated insulin secretion test (GSIS) confirmed that insulin secretion was normal in 
Ptpn2osb-/- mice (Fig. 3-4H).  Energy expenditure was also increased in Ptpn2osb-/- mice during the 
day cycle (Fig. 3-4J).  These results indicated that although the increase in activated osteocalcin 
of Ptpn2osb-/- mice was sufficient to affect insulin sensitivity and energy expenditure, it was 
insufficient to affect insulin secretion, glucose tolerance, and night cycle energy expenditure.  
The role of TC-PTP is not identical to that of ESP, as Esposb-/- mice suffer from both 
hypoglycemia and hyperinsulinemia and display increased energy expenditure in both day and 
night cycles (Lee et al., 2007).   
TC-PTP affects bone resorption through its expression in osteoblasts 
We had previously shown that insulin signaling in osteoblasts is a molecular determinant 
of osteocalcin bioactivity by promoting bone resorption.  Accordingly, bone resorption is higher 
in Esposb-/- mice that are a model of a gain of function of insulin signaling in osteoblasts and have 
an increase in active osteocalcin (Ferron et al., 2010a).  To determine whether TC-PTP regulates 
osteocalcin activity by utilizing the same mechanism of action, we asked whether TC-PTP 
influences bone resorption.   
For that purpose we performed a classical co-culture assay (Takahashi et al., 1988).  In 
this experiment, wild-type (WT) or Ptpn2-/- osteoblasts were cultured with WT monocytes in the 
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presence of VitD3 and PGE2 for 8 days.  At the end of the experiment, we stained for tartrate 
resistant acid phosphatase (TRAP), an enzyme expressed only in mature osteoclasts, to evaluate 
osteoclast differentiation (Burstone, 1959).  TRAP staining revealed that osteoblasts lacking TC-
PTP (Ptpn2-/-) induced greater osteoclast differentiation than WT osteoblasts, as quantified by 
number of TRAP-positive cells (Fig. 3-5A). Functional analysis confirmed that resorptive 
function of osteoclasts was also increased, as the resorptive pit area covered by osteoclasts co-
cultured with Ptpn2-/- osteoblasts was significantly larger than that of osteoclasts cultured with 
WT osteoblasts (Fig. 3-5B). Osteoblasts lacking TC-PTP (Ptpn2-/-) demonstrated decreased 
expression of Opg but no change in Rankl expression, as do Esp-/- osteoblasts (Fig. 3-5C) (Ferron 
et al., 2010a).  In addition, we observed an increase in expression of Ccl8, a monocyte 
chemoattractant supporting osteoclast formation (Fig. 3-5C) (Winslow et al., 2006).  These 
results confirmed that TC-PTP, primarily through its regulation of insulin signaling in 
osteoblasts, influences bone resorption.  Consistent with this contention, expression of Tcirg1, a 
gene expressed in osteoclasts but whose expression is regulated by insulin signaling in 
osteoblasts (Ferron et al., 2010a), was significantly increased in the osteoclasts cocultured with 
Ptpn2-/- osteoblasts (Fig. 3-5D).  The same was true for Clcn7, a chloride channel also regulating 
the acidity of the resorption lacunae (27, (Schaller et al., 2005), and Trap, a marker of osteoclasts 
(Andersson and Marks, 1989) (Fig. 3-5D).  Taken together, these experiments indicate that in 
cell culture, TC-PTP, presumably through its ability to inactivate the insulin receptor in the 
osteoblasts, affects Opg expression and thus regulates osteoclast differentiation and function.   
Accordingly, when compared to control littermates, Ptpn2osb-/- mice have increased 
osteoclast activity as demonstrated by increased serum levels of CTx, a marker of bone 
resorption  (Fig. 3-5E) (Rosen et al., 2000).  However, osteoclast number in these mice was not 
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significantly changed, indicating that in vivo deletion of TC-PTP is sufficient to affect osteoclast 
activity but not osteoclast number (Fig 3-5F).   
Bone histomorphometry analysis performed in vertebrae revealed that at 6 weeks of age, 
bone volume was slightly decreased, though this did not reach statistical significance (Fig. 3-5F).  
Osteoblast number and bone formation rate were also not significantly altered.  Primary 
osteoblasts lacking Ptpn2 similarly displayed no apparent proliferation and differentiation defect, 
as demonstrated by Van Kossa staining (Fig. 3-5F).  This result suggests that TC-PTP does not 
affect osteoblast proliferation and ability to differentiate.   
These data indicate that TC-PTP, by modulating insulin signaling in osteoblasts, is a 
determinant of osteoclast activity.  It is through this mechanism in which TC-PTP affects 
osteocalcin bioactivity, and thus insulin sensitivity. 
Discussion 
We demonstrate here that in addition to ESP, another tyrosine phosphatase TC-PTP, 
regulates whole-body insulin sensitivity and day cycle energy expenditure by increasing 
osteocalcin activity through its expression in the osteoblast.  These results further our 
understanding of the complexity of the regulation of osteocalcin activity and underscore the 
importance of the osteoblast as an endocrine cell type.   
Using substrate-trapping assays and loss-of-function models, we show that a function of 
TC-PTP is to attenuate insulin signaling in the osteoblast. In view of these results, we generated 
mice lacking TC-PTP specifically in the osteoblast (Ptpn2osb-/-) and observed that the level of 
circulating active osteocalcin is increased in these mice compared to their littermate controls.  
This corresponded to an increase in whole-body insulin sensitivity and day cycle energy 
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expenditure in Ptpn2osb-/- mice on a standard chow diet.  These mice are therefore, a partial 
phenocopy of Esposb-/- mice, which, in addition, display an increase in insulin secretion and 
increase in energy expenditure in the night cycle.  These results suggest that activated 
osteocalcin may differentially regulate insulin secretion and insulin sensitivity. Accordingly, 
target tissues may respond to different activation thresholds of osteocalcin.   
Though its role in the mouse osteoblast is more robust, ESP is non-functional in humans 
(Cousin et al., 2004a).  In contrast, TC-PTP is conserved in humans (PTPN2) and has been 
implicated as a susceptibility gene in early-onset Type I diabetes (Espino-Paisan et al., 2011).  
Though TC-PTP may have a more minor role in mouse osteoblasts, its function to regulate 
osteocalcin activity is translatable to humans.  Further study will be required to investigate 
whether ESP and TC-PTP regulate insulin signaling cooperatively in the mouse osteoblast.   
It thus remains to be seen if additional regulatory factors in the osteoblast are involved in 
the control of energy metabolism by bone.  That deletion of Ptpn2 in osteoblasts is insufficient to 
affect differentiation and proliferation is highly suggestive of the presence of other factors 
affecting insulin receptor signaling in osteoblasts (Fulzele et al., 2010).  In particular, the role of 
the other tyrosine phosphatases expressed in osteoblasts that can bind the insulin receptor, but 
that are not regulated by isoproterenol stimulation, will need to be investigated.  That Ptpn2 
expression is stimulated upon treatment of osteoblasts with isoproterenol also raises the question 
of whether osteoblast expression of Ptpn2 contributes to the sympathetic regulation of bone mass 
and/or glucose homeostasis (Hinoi et al., 2008; Kajimura et al., 2011). 
As insulin signaling in osteoblasts has been shown to favor bone resorption (Ferron et al., 
2010a), we also examined how TC-PTP deficiency in these cells affects osteoclast function.   A 
coculture system demonstrated that TC-PTP regulates the differentiation and resorptive activity 
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of osteoclasts though Opg expression in osteoblasts. Previous work had demonstrated a cell-
autonomous function of TC-PTP in hematopoietic cell differentiation (Simoncic et al., 2006; 
Simoncic et al., 2002).  Mice lacking TC-PTP globally exhibit an increase in osteoclast density 
and bone resorption (Doody et al., 2011).  The current work expands the importance of TC-PTP 
by showing that it is able to regulate differentiation cell non-autonomously.   
TC-PTP has been previously implicated in the regulation of metabolism, as demonstrated 
by its role in the liver and hypothalamus (Fukushima et al., 2010; Loh et al., 2011a). It also 
shares a phosphatase domain with that of PTP1B, the prototypical phosphatase of the insulin 
receptor and functional human homologue of ESP (Andersen et al., 2001; Ferron et al., 2010a). 
A ubiquitously expressed protein, PTP1B is implicated in the regulation of energy metabolism 
through its functions in muscle, fat, liver, and POMC-neurons of the brain (Agouni et al., 2011; 
Banno et al., 2010; Bence et al., 2006a; Delibegovic et al., 2007b; Delibegovic et al., 2009).  
Hence, we explored the possibility that PTP1B expression in the osteoblast may also contributes 
to the regulation of energy metabolism. In vitro experiments suggest that PTP1B does not seem 
to affect insulin receptor activation in osteoblasts, at least not to the same extent that TC-PTP 
does. Additionally, mice specifically lacking Ptpn1 in osteoblasts (Ptpn1osb-/-) have no apparent 
differences in body weight, glucose tolerance, and insulin sensitivity compared to control 
littermates when fed on a normal diet.  
That TC-PTP, but not PTP1B, regulates the osteocalcin activation pathway in mouse 
osteoblasts may be due to their relative levels of expression, as quantified by qPCR analysis (Fig. 
1F).  However, this difference may also be another example of divergent function between the 
two highly related phosphatases. Such a difference in the roles of PTP1B and TC-PTP has been 
documented for the regulation of cell spreading and adhesion (Stuible et al., 2008), pancreatic 
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islets response to ER stress (Bettaieb et al., 2011), as well as to the specificity of their substrates 
(Nievergall et al., 2010; Simoncic et al., 2006; Simoncic et al., 2002; Xu and Qu, 2008).  In 
addition, PTP1B and TC-PTP have been shown to contribute differentially to glucose 
homeostasis through their expression in the muscle (Loh et al., 2011b). Evidence from previous 
studies has also indicated that at a molecular level, the difference in PTP1B and TC-PTP 
regulation of the insulin receptor can be dissected to the level of the phosphorylated residue 
(Galic et al., 2005).  
This work extends our understanding of the bone regulation of energy metabolism, by 
identifying TC-PTP as an additional regulator of the osteocalcin-activation pathway. The finding 
that TC-PTP, a bona fide phosphatase of the insulin receptor, functions in osteoblasts to affect 
insulin sensitivity further establishes the role of insulin signaling in bone remodeling and energy 
metabolism.    
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Figure 3-1. Identifying PTP(s) that parallel ESP. 
(A) In vitro substrate trapping. Extracts from pervanadate-treated ROS17/2.8 cells were pulled 
down using GST only or DA mutants of PTP GST-fusion proteins. InsRβ was detected by 
western blot. An anti-phosphotyrosine (α-pTyr) was used for detection. (B) Stimulation of 
primary osteoblasts with isoproterenol (10µM). (C) In vivo substrate trapping. WT and DA 
FLAG tagged PTP1B and TC-PTP proteins were immunoprecipitated from ROS17/2.8 cells after 
15 min stimulation with insulin (100 nM) (deleted). Immunoprecipitated proteins (IP) and total 
cell lysates were then analyzed by western blot. (D) qPCR expression analysis across different 
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tissues. (E) Expression analysis by western blot. (F) qPCR expression analysis in proliferative 





Figure 3-2. Generation of Ptpn2osb-/- and Ptpn1osb-/- mice. 
(A) Generation of the Ptpn2 floxed allele. (B) Deletion of the Ptpn2 allele in indicated tissues. 
(C) qPCR analysis of Ptpn2 expression in bone marrow derived osteoblasts (normalized to 
osteocalcin expression). (D) Generation of the Ptpn1 floxed allele. (E) Deletion of the Ptpn1 
allele in indicated tissues. (F) qPCR analysis of Ptpn1 expression in bone marrow derived 





Figure 3-3. TC-PTP regulates insulin receptor phosphorylation in osteoblasts. 
(A) Phosphorylation of the insulin receptor β-subunit 5 minutes post-treatment with insulin 
(10nM) in mouse primary osteoblasts. Quantification of signal normalized to IRβ using ImageJ. 
(B) Expression of the insulin target gene Gsy1 in primary osteoblasts. Treatment of control is 
with 10nM insulin. (C) Phosphorylation of the insulin receptor β-subunit in whole calvaria after 





Figure 3-4. Improved insulin sensitivity in Ptpn2osb-/- mice. 
(A, B) Total GLU13 osteocalcin levels in male (A) Ptpn2osb-/- and (B) Ptpn1osb-/- mice. (C, D) 
Glucose tolerance tests (GTTs) on male (C) Ptpn2osb-/- and (D) Ptpn1 osb-/- mice.  (E, F) Insulin 
tolerance tests (ITTs) on male (E) Ptpn2osb-/- and (F) Ptpn1 osb-/- mice.  (G) Area under the curve 
of (E). (H) Glucose stimulated insulin secretion test (GSIS) of Ptpn2osb-/- male mice. (I) GTT on 




Figure 3-5. TC-PTP in osteoblasts regulates osteoclast differentiation. 
(A) Representative pictures of TRAP staining of osteoclasts cocultured in the presence of WT or 
Ptpn2-/- osteoblasts.  Quantification of the number of TRAP-positive cells. (B) Representative 
pictures of resorptive activity of osteoclasts cocultured in the presence of WT or Ptpn2-/- 
osteoblasts.  Quantification of resorptive pit area.  (C) qPCR analysis of Opg, Rankl, and Ccl8 
expression in WT or Ptpn2-/- osteoblasts cocultured with osteoclasts. (D) qPCR analysis of 
Tcirg1, Trap, and Clcn7 expression in osteoclasts cocultured in presence of WT or Ptpn2-/- 
osteoblasts. (E) CTx serum levels in 6 week-old mice.  (F) Representative pictures and 
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Histomorphometric analysis of Ptpn2osb-/- mice and control Ptpn2fl/fl littermates. Bone 
Volume/Tissue Volume (BV/TV), Number of Osteoclasts/ Trabecular Area (N.Oc/T.Ar), 
Number of Osteoblasts/Trabecular Area (N.Ob/T.Ar), Bone Formation Rate/Bone Surface 





Chapter Four: Additional results and discussion 
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Ebf1 cell non-autonomous regulation of bone mass accrual 
The finding that Ebf1 does not regulate osteoblast number cell-autonomously raises the 
following question: how does Ebf1 regulate bone mass accrual?  There are many different tissues 
in which Ebf1 may be involved in regulating bone formation.   
Previous studies have demonstrated that white adipose tissue, pancreas, and gut are all 
sources of hormones that affect bone formation.  White adipose tissue is the source of the 
hormone leptin, which binds to its receptors in the brainstem to decrease serotonin.  This results 
in an increase of the sympathetic tone, an inhibitor of osteoblast proliferation (Ducy et al., 2000; 
Takeda et al., 2002).  Insulin, produced in the β-islet cells of the pancreas, promotes osteoblast 
proliferation and differentiation (Fulzele et al., 2010).  Peripheral serotonin produced by the 
enterochromaffin cells of the gut, binds to its receptor Htr1b on the osteoblast to inhibit 
proliferation (Yadav et al., 2008).     
Ebf1 may not regulate bone mass accrual through its expression in the adipocyte 
To begin addressing the question of how Ebf1 non-autonomously regulates osteoblast 
proliferation, we took cues from the phenotype of Ebf1-/- mice.  These mice showed no 
significant changes in insulin levels, but did display a significant decrease in serum leptin, the 
inhibitor of bone mass accrual mentioned above (Fretz et al., 2010).  We studied the role of Ebf1 
in white adipocytes because Ebf1-/- mice are deficient in leptin, and also because white 
adipocytes are derived from the same mesenchymal progenitor as osteoblasts.  Since MSCs give 
rise to all mesenchymal cell types, it is conceivable that additional transcription factors may 
promote differentiation along one lineage at the expense of differentiation along another.  In 
particular, the possibility of reciprocal lineage choice between osteoblasts and adipocytes has 
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long been considered since the fat content of bones often increases when the number of 
osteoblasts and bone mass decreases (Rosen et al., 2009).  Specifically, PPARγ favors adipocyte 
differentiation but inhibits osteoblast differentiation (Akune et al., 2004).  We attempted to 
address the possibility that Ebf1 affects bone mass accrual through its expression in the white 
adipocytes.  We performed expression analysis, cell culture experiments, and in vivo adipocyte-
specific ablation of Ebf1 using mice harboring a floxed allele of Ebf1 that were crossed to ap2-
Cre transgenic mice.   
Previous experiments showed expression of Ebf1 in white adipose tissue (Figure 2-1C).  
Using exonic qPCR primers normalized to genomic DNA, we confirmed that Ebf1 was the most 
highly expressed of the Ebf family of transcription factors in primary white adipocytes (Figure 4-
1A).  Analysis of Ebf1 expression in the embryonic fat depot at E14.5 and E16.5 also show that 
Ebf1 transcript is present during development but very low levels.  This low expression 
coincided with the strong one of C/ebpα, a determinant of white adipogenesis (Figure 4-1B). 
   We then examined whether decreasing Ebf1 expression in a multipotential progenitor 
cell line, 10T1/2 cells, would promote expression of osteoblastic genes at the expense of 
adipocytic genes (Figure 4-2).  Decreasing Ebf1 expression by 94% resulted in a significant 
down-regulation of the major transcription factors responsible for determining adipocyte cell 
fate, i.e. PPARγ, C/EBPα, C/EBPβ, and Prdm16.  In addition, expression of two adipokines 
Adiponectin and Resistin was similarly decreased.  However, not all genes were equally affected.  
For instance, C/EBPδ and interestingly, Leptin, expression was unaffected by the decrease in 
Ebf1 expression.  Concurrently, Ebf1 knockdown in 10T1/2 cells resulted in an almost four-fold 
upregulation of the main determinant of osteoblast differentiation, Runx2, and of several genes 
expressed in osteoblasts, such as Col1a1, Alkaline phosphatase (Alpl), and Osteoprotegerin 
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(Figure 4-2).  In addition, ChIP analysis performed in 10T1/2 cells did not reveal Ebf1 binding to 
the promoters of any adipocyte-specific genes, only the Alpl gene which is expressed in 
osteoblasts (Figure 2-2B). Again, not all osteoblast-specific genes were affected by the down-
regulation of Ebf1.  Its knockdown did not affect expression of Osterix, Atf4, or Osteocalcin 
Next, to further address this question we generated mice lacking Ebf1 in adipocytes, 
crossing mice with a floxed allele of Ebf1 with mice expressing Cre recombinase under the 
control of the aP2 promoter.  We confirmed that Ebf1adp-/- mice lacked Ebf1 in the adipose tissue 
only (Figure 4-3).  Ebf1adp-/- mice were born at the expected Mendelian ratio, indicating that 
complete Ebf1 expression in cells of the adipocyte lineage is not necessary for embryonic 
development.  At 1-month of age, Ebf1adp-/- mice had normal body and epididymal fat pad 
weights (Figure 4-4A).  Fat histological analysis further confirmed that adipocytes were present.  
Moreover, the relative distribution of adipocyte cell area was comparable in Ebf1adp-/- and wild-
type littermates (Fig. 4-4B).  More surprisingly, and unlike what we observed in cell culture, 
expression of adipocyte and osteoblast marker genes was not affected by the absence of Ebf1 in 
adipocytes (Fig. 4-4C).  Altogether, these results indicate that, in the conditions of this 
experiment, Ebf1 does not appear to noticeably affect cell differentiation in vivo.  
 We also analyzed the skeleton of these animals. Bone histomorphometric analysis 
performed at 1-month of age failed to show any change in bone mass, osteoblast number, and 
bone formation rate in Ebf1adp-/- mice (Fig. 4-4D).  These data indicate that removal of Ebf1 from 
aP2-expressing adipocytes also does not overtly affect osteoblast differentiation.  
 We cannot exclude, however, the possibility that complete deletion of Ebf1 or its removal 
in mesenchymal progenitor cells affects adipocyte and osteoblast differentiation.  Unfortunately, 
no Cre driver line is yet available to address this question in vivo.  That Ebf1 does not affect 
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Leptin expression suggests that it does not regulate bone mass accrual by modulating adipocyte 
production of leptin.  The possibility that Ebf1 may be affecting bone mass accrual through its 
action in the certain cells of the brain, pancreas, gut, or other tissue(s), will need to be further 
tested.  
The effect of Ptpn2 deletion on insulin sensitivity decreases with age 
 The improved insulin sensitivity of Ptpn2osb-/- mice was observed at 6 weeks of age.  To 
determine if this insulin sensitivity was sustained as mice age, we tested the insulin sensitivity of 
older Ptpn2osb-/- mice at 3 and 5 months of age.  Compared to their wild-type littermates, insulin 
sensitivity of 3-month old Ptpn2osb-/- mice was only moderately increased.  At only two time 
points of the insulin tolerance test did the Ptpn2osb-/- mice show significant improvement.  In 
addition, the p-value accompanying the change in area under the curve was slightly above the 
point of significance (Figure 4-5A).  Interestingly, the gonadal fat pad weight of 3-month old 
Ptpn2osb-/- mice was significantly smaller compared to their wild-type littermates, a difference 
that was not observed in 6-week old mice (Figure 4-5B).  By 5 months of age, any improvement 
of Ptpn2osb-/- insulin sensitivity had disappeared (Figure 4-5C).  This was noteworthy as the 
improved insulin sensitivity and glucose tolerance of Esp and Esposb -/- mice diminished by the 
time the mice reached 3 months of age.  
That the phenotype of both osteocalcin gain-of-function models disappears with age 
raises additional questions.  Does undercarboxylated osteocalcin lose its insulin-sensitizing 
capability with age-related insulin resistance?  Do insulin-responsive tissues develop 
“osteocalcin resistance?”   
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It may also be possible that, with age, other PTPs begin to compensate for a lack of ESP 
or TC-PTP in osteoblasts. Increased PTP expression or activity may in fact contribute to the 
pathology of insulin resistance, as PTP expression has been shown to increase in an obesity state 
(Bence et al., 2006) (Loh et al., 2011).  Further tests will need to be performed to determine if 
age and/or obesity increase the activity of PTPs in osteoblasts. 
TC-PTP and ESP regulation of insulin signaling 
 TC-PTP is a negative regulator of insulin in the osteoblast, controlling whole-body 
insulin sensitivity and night-time energy expenditure through its regulation of osteocalcin 
activity.  Its function parallels that of ESP action in the osteoblast.  However, Ptpn2osb-/- mice do 
not recapitulate the glucose intolerance and day-time increased energy expenditure observed in 
that of Esposb-/-, suggesting that there exists a dissociation between osteocalcin action on insulin 
sensitivity and insulin secretion.  In contrast to what has been previously observed, our results 
suggest that the threshold to affect insulin sensitivity is lower than that of insulin secretion 
(Ferron et al., 2008). 
The difference among the various mutant mouse strains raises the question: do TC-PTP 
and ESP regulate insulin signaling in the osteoblast in a redundant, coordinated, or non-
overlapping manner?  To begin to address this question, we performed insulin tolerance tests on 
Ptpn2osb-/-;Esposb-/- mice to determine if TC-PTP and ESP function synergistically in the 
osteoblast to regulate whole-body insulin sensitivity.  We tested these double mutant mice at 6 
weeks of age, a time point in which the phenotype of Ptpn2osb-/- display marked increased insulin 
sensitivity. However, we were unable to observe an increase in insulin sensitivity when mice 
lack both Ptpn2 and Esp in the osteoblast, suggesting that TC-PTP and ESP may not be 
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coordinated in their regulation of insulin signaling (Figure 4-6).  A caveat of this experiment, 
however, was the absence of a discernable change in insulin sensitivity of Esposb-/- mice at 6-
weeks of age (Figure 4-6).  These mice displayed an improvement in insulin sensitivity at 4-
weeks of age, (Lee et al., 2007).  Further analysis will be needed to address whether TC-PTP and 
ESP affect insulin sensitivity in a coordinated manner.   
 It may be useful to study the dynamics of ESP and TC-PTP regulation of the insulin 
receptor in the osteoblast. Previous studies in transformed mouse embryonic fibroblasts have 
demonstrated that TC-PTP is coordinated with PTP1B in the regulation of the insulin receptor.  
Regulation of the Y1162/Y1163 phosphorylation site differs between them in that TC-PTP is 
responsible for the sustained signal while PTP1B regulates signal intensity (Galic et al., 2003).  
As ESP and TC-PTP are localized to different regions of the cell, it is probable that their roles 
may also differ temporally.  Further experiments will need to be performed to address the 
dynamics of ESP and TC-PTP.   
Does TC-PTP regulation of osteocalcin bioactivity affect male fertility? 
 Osteocalcin increases the production of testosterone in males, and ESP has been shown to 
regulate the osteocalcin-testosterone axis.  We measured testis weight in 3-month old Ptpn2osb-/- 
males, the same age in which Esp-/- and Ocn-/- mice were analyzed for fertility (Figure 4-7) (Oury 
et al., 2011).  Unlike what was observed in Esp-/- mice, however, we did not see a difference in 
testis weight. The possibility that TC-PTP may regulate the osteocalcin-testosterone axis remains 
to be more fully explored.    
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Are there other TC-PTP substrates in the osteoblast? 
 We have observed that the IGF-1R receptor is an in vitro substrate of PTP1B, TC-PTP, 
and ESP (Figure 4-7).  A GST-pull down performed ROS cells reveals that PTP1B, TC-PTP, 
ESP, but not PTPRJ, bind insulin-like growth factor type 1 receptor (IGF-1R) (Figure 4-8).  
Interestingly, TC-PTP and ESP wild-type mutants can bind to IGF-1R independently of their 
catalytic domain (Figure 4-8). IGF-1R has previously been shown to be necessary in osteoblasts 
for growth hormone (GH)-dependent proliferation (Fulzele et al., 2010) (DiGirolamo et al., 
2007).  However, in our studies, we did not observe an increase in osteoblast number in Ptpn2-/- 
mice (Figure 3-5G,F).  The possibility remains that TC-PTP has additional substrates in the 
osteoblast.  
Does TC-PTP regulate hematopoiesis through its expression in the osteoblast? 
 TC-PTP has been shown to be an important regulator of hematopoiesis and the immune 
response.  Through cell-autonomous regulation of the JAK/STAT pathway and CSF-1 signaling, 
TC-PTP regulates cytokine production and mononuclear infiltrates (ten Hoeve et al., 2002) 
(Simoncic et al., 2002).  The demonstration that TC-PTP regulates osteoclast maturation through 
its expression in the osteoblast suggests that development of other hematopoietic cells may also 
be affected by TC-PTP function in the osteoblast.  In fact, TC-PTP has been shown to regulate 
B-cell development through its expression in bone marrow stromal cells that express interferon-γ 
(Bourdeau et al., 2007). 
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What is the role of TC-PTP in human osteoblasts? 
 SNPs in the human PTPN2 gene have been associated with the development of type 1 
diabetes (Smyth et al., 2008) (Espino-Paisan et al., 2011).  Since the skeleton is an important 
contributor to whole body glucose homeostasis, it is possible that TC-PTP plays an important 
role in human osteoblasts to regulate whole-body insulin sensitivity.  To gain a better 
understanding of its role in humans, TC-PTP function should be studied in the context of a 
human osteoblast cell, similar to what has been previously done with the study of human PTP1B  
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Figure 4-1. Ebf1 expression analysis in adipocytes. (A) Normalized expression of Ebf1, 2, 3, 
and 4 by qPCR in primary adipocytes. (B) Expression pattern analysis of Ebf1 by (radioactive in 
situ hybridization of adjacent sections featuring the embryonic (C/EBPα) fat depot in mouse 












Figure 4-3. Deletion of the Ebf1 allele in indicated tissues. 





Figure 4-4. Phenotype analysis of Ebf1adp-/-. (A) Body weight, percent gonadal fat (FPW/BW), 
body length, and femur length (B) distribution of adipocyte cell size (C) qPCR analysis of white 








Figure 4-5. Insulin sensitivity of aged Ptpn2osb-/- mice. (A) Insulin tolerance test on 3-month 
old Ptpn2osb-/- male mice with the area under the curve.  (B) Fat pad weight of 3-month old 





Figure 4-6. Insulin sensitivity of Ptpn2osb-/-;Esposb-/- double knockout mice. Insulin tolerance 










Figure 4-8. In vitro substrate trapping. Extracts from pervanadate-treated ROS17/2.8 cells 
were pulled down using GST only or DA mutants of PTP-GST fusion proteins. Insulin-like 









Mice lacking the transcription factor Ebf1 in all cells have high bone mass due to an 
increase in bone formation (Hesslein et al., 2009).  To test this whether Ebf1 inhibits osteoblast 
function, we analyzed Ebf1 function in primary osteoblasts and in vivo through osteoblast-
specific inactivation in in the mouse, and demonstrated that deletion of Ebf1 in early osteoblast 
cells does not increase osteoblast differentiation or function. 
The finding that the Ebf1 does not regulate bone mass through its expression in the 
osteoblast demonstrates that this transcription factor regulates bone formation through its 
expression in another cell type.  One distinct possibility is that Ebf1 regulates bone mass through 
its expression in the dorsal root ganglia and spinal cord, areas that contain the axons of primary 
afferent neurons and that we have identified as expressing Ebf1 at high levels (unpublished data).  
That the central nervous system plays an important role in the regulation of bone remodeling has 
been previously established with the discovery that leptin inhibits bone formation via a 
hypothalamic relay and mediation of the sympathetic tone	  (Ducy et al., 2000)	  (Yadav et al., 
2009).  The sympathetic signal is thus sensed by osteoblasts, which express functional β2-
adrenergic receptors on their cell surface	  (Takeda et al., 2002).  The discovery of a brain-bone 
link suggests that bone remodeling is tightly controlled by the nervous system, and this 
relationship may indeed extend beyond that of hormonal control, suggested by the presence of 
afferent neurons that physically connect the bone to the central nervous system.  Yet the 
mechanisms through which sensory neurons regulate bone formation and/or bone resorption are 
unidentified (Chenu, 2004)	  (Elefteriou, 2008).  I propose here that Ebf1 regulation of bone mass 
accrual occurs through its expression and function in afferent neurons, and that Ebf1 acts as a 
repressor of sensory neuron activation. 
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 The clinical observation that pain is experienced in the bones has long indicated that the 
skeleton is innervated with sensory neurons.  The activity of sensory neurons in the bone may be 
important for two main reasons.  First, the nervous system must be able to sense skeletal fracture 
in order to stimulate endochondral ossification and bone remodeling at the site of trauma.  
Secondly, the skeleton must also sense changes in mechanical load in order for it to adapt to 
changes in weight and external impact.  This functional adaptation is supported by observations 
in human studies that describe strong correlations between high-impact exercise and increased 
osteogenic response resulting in high bone mass; in contrast, inactivity is associated with 
diminished bone mass (Bassey and Ramsdale, 1994)	  (Courteix et al., 1998)	  (Robinson et al., 
1995)	  (Taaffe et al., 1997)	  (Chenu, 2004).  It has since been demonstrated experimentally in 
rodents that mechanical stress and loading are important factors in the determination of bone 
volume in both cortical and trabecular regions (Mosley and Lanyon, 1998; Sugiyama et al., 
2010)	  (Sugiyama et al., 2010)	  (Carter et al., 1987).  These results are supported by a 
computational simulation model that confirms trabecular bone architecture is highly adaptive to 
mechanical load	  (Huiskes et al., 2000).  
The most recognized site of nociception in the skeleton is at the periosteum, the 
connective membrane that surrounds the outer cortex of mineralized bone, excluding the joints of 
long bone.  The periosteum is composed of two layers: its outer layer consists of fibroblasts and 
collagen, while the inner bone collar is made up of mainly osteoprogenitor cells that are recruited 
to expand the cortical thickness of bone and repair fractures. Nerve endings, including those of 
the peptidergic calcitonin-gene related peptide immunoreactive (CGRP-ir), as well as myelinated 
sensory neurons, are found within the inner periosteum region in close proximity to osteoblast 
progenitors and within the Haversian and Volkman’s canals of the compact bone (Hara-Irie et 
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al., 1996) (Mach et al., 2002).  Interestingly, CGRP-ir fibers surrounding the bone collar undergo 
rapid proliferation and sprouting upon bone fracture, demonstrating that these neurons are 
responsive to changes in bone integrity and thus, may have an important role in fracture repair 
(Hukkanen et al., 1993). 
It has been long thought that the periosteum is the only area of nociception in the 
skeleton.   However, studies have identified CGRP-ir fibers, myelinated sensory fibers, and 
sympathetic nerve fiber endings in the regions of mineralized bone and bone marrow, and at a 
higher density than that of the periosteum when calculated per volume (Kuntz and Richins, 1945; 
Serre et al., 1999) (Mach et al., 2002). The direct contact of nerve fibers with osteoblasts in these 
areas suggests a regulatory role for sensory input in the regulation of bone turnover and 
remodeling in not only cortical bone, but also in the trabecular areas that are responsive to 
mechanical load and stress.        
The cell bodies of primary afferent neurons, whose synaptic terminals reach into the 
spinal cord for signal transduction to the brain, are contained in the dorsal root ganglia.  Ebf1 
expression is high in both the dorsal root ganglia and spinal cord, suggesting that this 
transcription factor may affect the ability of sensory neurons to transmit signals to the central 
nervous system.  That rapid and ubiquitous osteoporosis develops following spinal cord injury 
demonstrates that intact spinal cord function is critical for the maintenance of bone mass.  This 
observation, combined with analysis showing high bone mass in Ebf1-/- mice, indicates that if 
Ebf1 were to function in sensory neurons, it would be a repressor of afferent neuron activation. 
In support of this hypothesis is the observation that Ebf1 can function as both an activator 
and repressor.  In B cells, Ebf1-repressed targets display a loss of activating chromatin marks 
and gain of H3K27 trimethylation (Treiber et al., 2010).  ChIP-seq can be performed in isolated 
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dorsal root ganglia and spinal cord tissue to identify these Ebf1 target genes, similar to what has 
been previously done in B cells (Treiber et al., 2010). As a “pioneer factor,” Ebf1 may be 
involved in early specification sensory neuronal fate or the expression of neurotrophic factors 
that are important for sensory neuronal survival.   
Furthermore, to test the hypothesis that Ebf1 regulates afferent neuron activation in vivo, 
Ebf1 should be genetically ablated specifically in primary afferent neurons.  Ebf1fl/fl  mice should 
be crossed to mice expressing Cre Recombinase under the control of a promoter expressed 
specifically in primary afferent neurons – for example: Prph-Cre or Pvalb-Cre.  If the above 
hypothesis is correct, Ebf1DRG-/-  mice will display an increase in bone mass as a result of increase 
bone formation and decreased osteoclast function, similar to what was observed in Ebf1-/- mice 
(Hesslein et al., 2009).   
In addition to high bone mass and a lack of B cells (Hesslein et al., 2009; Lin and 
Grosschedl, 1995), Ebf1-/- mice display runted growth, decreased body adipose, increased 
marrow adipose, and abnormal glucose metabolism (Fretz et al., 2010), conditions that may all 
contribute to the low survival rate of these knockout mice on the C57Bl/6 genetic background.  
That Ebf1-/- mice have a multitude of abnormalities further supports the hypothesis that Ebf1 
functions in the central nervous system, and suggests that Ebf1-/- mice are a gain-of-function of 
sensory neuron activation.  It would be interesting to see if Ebf1 deletion in the dorsal root 
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